acebutolol has been researched along with ferric carboxymaltose in 417 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (3.36) | 29.6817 |
| 2010's | 264 (63.31) | 24.3611 |
| 2020's | 139 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, JB; Mangione, A; Martens, MG; Seid, MH; Van Wyck, DB | 1 |
| Bejenariu, C; Breymann, C; Gliga, F; Strizhova, N | 1 |
| D'Haens, G; Dudar, LV; Garcia, LC; Gasche, C; Karnafel, W; Kulnigg, S; Sambuelli, AM; Simanenkov, V; Stoinov, S | 1 |
| Birgegård, G; Hedenus, M | 1 |
| Urato, AC | 1 |
| Baker, JB; Banach, W; Derman, RJ; Goldberg, C; Rogers, R; Seid, MH | 1 |
| Cropper, L; Pugh-Clarke, K; Tagboto, S; Turner, J | 1 |
| Cohen, CD; Fehr, T; Grimmelt, AC; Serra, AL; Wuethrich, RP | 1 |
| Keating, GM; Lyseng-Williamson, KA | 1 |
| Goodnough, LT; Hadley, PE; Jehle, JA; Mangione, A; Morrison, J; Van Wyck, DB | 1 |
| García-Erce, JA; Gómez-Ramírez, S; Muñoz, M | 1 |
| Anker, SD; Colet, JC; Dickstein, K; Drexler, H; Filippatos, G; Lüscher, TF; Mori, C; Pocock, S; Ponikowski, P; Poole-Wilson, PA; von Eisenhart Rothe, B; Willenheimer, R | 1 |
| Bailie, GR; Mason, NA; Valaoras, TG | 1 |
| Dec, GW | 1 |
| Anker, SD; Banasiak, W; Bart, B; Comin Colet, J; Dickstein, K; Drexler, H; Filippatos, G; Kirwan, BA; Lüscher, TF; Mori, C; Niegowska, J; Pocock, SJ; Ponikowski, P; Poole-Wilson, PA; von Eisenhart Rothe, B; Willenheimer, R | 1 |
| Covic, A; Mircescu, G | 1 |
| Jelani, QU; Katz, SD | 1 |
| Bregman, DB; Butcher, A; Goodnough, LT; Harrington, RA; Koch, TA; Morris, D; Onken, JE; Szczech, LA; Wolf, M | 1 |
| Marx, JJ | 1 |
| Canclini, C; Funk, F; Geisser, P; Neiser, S; Ryle, P | 1 |
| Malek, A | 1 |
| Banké-Bochita, J; Geisser, P | 1 |
| Geisser, P; Rumyantsev, V | 1 |
| Bailie, GR | 1 |
| Mani, LY; Nseir, G; Pascual, M; Venetz, JP | 1 |
| Benjamin, J; Mangione, A; Martinez, C; Qunibi, WY; Roger, SD; Smith, M | 1 |
| Bager, P; Dahlerup, JF | 1 |
| Anker, SD; Jankowska, EA; Ponikowski, P; von Haehling, S | 1 |
| Auerbach, M; Ballard, H | 1 |
| Gozzard, D | 1 |
| Cowie, MR; Lucas, R | 1 |
| Bokemeyer, B; Chopey, IV; Evstatiev, R; Gasche, C; Gutzwiller, FS; Iqbal, T; Khalif, IL; Marteau, P; Riopel, L; Stein, J | 1 |
| Gisbert, JP; Gomollón, F | 2 |
| Bisbe, E; Díez-Lobo, AI; García-Erce, JA; Muñoz, M | 1 |
| Angerosa, M; Cao, G; Oliveri, L; Toblli, JE | 1 |
| Adler, CH; Allen, RP; Bregman, DB; Butcher, A; Du, W; Earley, CJ | 1 |
| Bugat, R; de Pouvourville, G; Luporsi, E; Mahi, L; Morre, C; Wernli, J | 1 |
| Doll, D; Ertmer, C; Hagemann, O; Hahnenkamp, K; Hönemann, CW; Kampmeier, T | 1 |
| Beigel, F; Brand, S; Breiteneicher, S; Göke, B; Laubender, RP; Löhr, B; Ochsenkühn, T; Schnitzler, F; Seiderer, J; Tillack, C; Weidinger, M | 1 |
| Anker, SD; Comin-Colet, J; Dickstein, K; Filippatos, GS; Johnson, P; Lainscak, M; Lüscher, TF; Mori, C; Ponikowski, P; Willenheimer, R | 1 |
| Aparicio, R; Bernabeu-Wittel, M; Melero-Bascones, M; Monte-Secades, R; Montero, A; Murcia-Zaragoza, J; Romero, M; Rosso, C; Ruiz-Cantero, A | 1 |
| Andersson, M; Kurtzhals, JA; Maretty, L; Sharp, RE | 1 |
| Martín-Montañez, E; Muñoz, M | 1 |
| Hornyak, M; Kassubek, J; Kiemen, A; Scholz, H | 1 |
| Beaumont, C; Denamur, E; Driss, F; El Benna, J; Heming, N; Lasocki, S; Lettéron, P; Millot, S; Montravers, P; Tourret, J | 1 |
| Anker, SD; Blank, PR; Braunhofer, PG; Gutzwiller, FS; Mori, C; Ponikowski, P; Schwenkglenks, M; Szucs, TD | 1 |
| Javidroozi, M; Shander, A | 1 |
| Hoo, ZH; Wildman, MJ | 1 |
| Christoph, P; Pfenniger, A; Schuller, C; Surbek, D | 1 |
| Bhandari, S; Muñoz, M; Reinisch, W; Staun, M | 1 |
| Christoph, P; De Tejada, BM; Irion, O; Schuller, C; Studer, H; Surbek, D | 1 |
| Hutchings, A; Jeans, A; Macdougall, IC; Wilson, PD | 1 |
| Calvet, X; Dosal, A; Figuerola, A; Gené, E; López, M; Miquel, M; Moreno, L; Ruíz, MÀ; Suarez, D; Villoria, A | 1 |
| Franzem, M; Harlin, O; Klement, B; Marschner, N; Rohrberg, R; Steinmetz, T; Tesch, H; Tschechne, B; Wamhoff, J | 1 |
| Alexeeva, O; Bokemeyer, B; Chopey, I; Evstatiev, R; Felder, M; Gasche, C; Gudehus, M; Iqbal, T; Khalif, I; Marteau, P; Stein, J | 1 |
| Bernardo, MV; Bregman, DB; Butcher, A; Charytan, C; Koch, TA; Morris, D | 1 |
| Geisser, P; Macdougall, IC | 1 |
| Bregman, DB; Goodnough, LT; He, A; Koch, TA; Morris, D | 1 |
| Arneth, B; Bornstein, SR; Fischer, S; Julius, U; Schatz, U; Siegels, D; Siegert, G | 1 |
| Bregman, DB; Koch, TA; Wolf, M | 1 |
| Barish, C; Bregman, D; He, A; Malone, M | 1 |
| Anker, SD; Conraads, VM; Gaudesius, G; Greenlaw, N; Mori, C; Ponikowski, P; Van Craenenbroeck, EM | 1 |
| Cabré, C; Font, R; García-Ruiz, C; Jariod, M; Martínez-Vea, A; Muñoz-Cortés, M; Nogués, MR; Prats, M; Romeu, M | 1 |
| Evstatiev, R; Gasche, C; Howaldt, S; Kamali, H; Kulnigg-Dabsch, S; Mickisch, O; Schmid, W; Stein, J; Volf, I; Waldhör, T | 1 |
| Biggar, P; Hahn, KM | 1 |
| Bailie, GR; Leggett, RE; Levin, R; Li, H; Li, HD; Patadia, H; Schuler, C | 1 |
| Amet, S; Deray, G; Janus, N; Launay-Vacher, V; Mahi, L; Rey, JB; Rouillon, L; Scotte, F; Zakin, L | 1 |
| Münch, HG; Potthoff, SA | 1 |
| Acs, P; Akright, B; Barish, C; Bhaskar, BS; Bregman, DB; Butcher, A; Goodnough, LT; Harrington, RA; Koch, TA; Morris, D; Onken, JE; Smith-Nguyen, GN | 1 |
| Anker, SD; Colet, JC; Dickstein, K; Farmakis, D; Filippatos, G; Ford, I; Gaudesius, G; Greenlaw, N; Lüscher, TF; Mori, C; Parissis, J; Ponikowski, P; von Eisenhart Rothe, B; Willenheimer, R | 1 |
| Weiss, G | 1 |
| Anker, SD; Braunhofer, PG; Comin-Colet, J; Filippatos, G; Gutzwiller, FS; Mori, C; Pfeil, AM; Ponikowski, P; Schwenkglenks, M; Szucs, TD | 1 |
| Anderson, B; Anson, JM; Cardoso, T; Fallon, KE; Fazakerley, R; Garvican, LA; Gore, CJ; Lobigs, LM; Macdougall, IC; Saunders, PU; Thompson, KG | 1 |
| Bajor, A; Befrits, R; Blom, H; Blomquist, L; Hammarlund, P; Hjortswang, H; Klintman, D; Wikman, O | 1 |
| Cabré, C; Font, R; García, C; Jariod, M; Prats, M; Vea, AM | 1 |
| Achermann, R; Giger, M | 1 |
| Thompson, CA | 1 |
| Bregman, DB; Buerkert, J; Butcher, A; Goodnough, LT; Hamerski, D; Harrington, RA; Iftikhar, H; Koch, TA; Mangoo-Karim, R; Martin, ER; Martinez, CO; Morris, D; Newman, GE; Onken, JE; Qunibi, WY; Ross, DL; Singh, B; Smith, MT | 1 |
| Braunhofer, P; Brock, E; Schneider, H; Troxler, J | 1 |
| Bock, A; Carrera, F; Cushway, T; Eckardt, KU; Gaillard, C; Macdougall, IC; Roger, SD; Roubert, B; Van Wyck, D | 1 |
| Coyne, DW; Larson, DS | 1 |
| Barea Mendoza, JA; González Olmedo, J; Gredilla Zubiría, I; Mateo Alvarez, S | 1 |
| Coti Bertrand, P; Fierz, YC; Gonthier, A; Kenmeni, R; Lier, F; Pralong, F | 1 |
| Collingwood, J; Dekker, G; Froessler, B; Hodyl, NA | 1 |
| Cabré, C; Font, R; García, C; Giralt, M; Jariod, M; Martinez-Vea, A; Muñoz-Cortés, M; Prats, M; Romeu, M | 1 |
| Bae, JM; Kim, MJ; Kim, YW; Nam, BH; Park, YK; Reim, D; Roh, SH; Yook, JH; Yu, WS | 1 |
| Anker, SD; von Haehling, S | 1 |
| Balck, K; Breymann, C; Favrat, B; Gasche, C; Hedenus, M; Keller, T; Mezzacasa, A | 1 |
| Arroyo, R; Bisbe, E; Moltó, L; Muniesa, JM; Tejero, M | 1 |
| Hiller, E | 1 |
| Baldus, S; Dumitrescu, D; Gerhardt, F; Knoop-Busch, S; Rosenkranz, S; Rudolph, TK; ten Freyhaus, H; Viethen, T | 1 |
| Bock, AH; Carrera, F; Eckardt, KU; Gaillard, C; Macdougall, IC; Nolen, JG; Roger, SD; Roubert, B; Van Wyck, D | 1 |
| Acheson, AG; Brookes, MJ; Iqbal, T; Keeler, BD; Ng, S; Simpson, JA; Tselepis, C | 1 |
| Bizot, P; Carlier, L; Chaudet, A; Lasocki, S; Rineau, E | 1 |
| Angerosa, M; Cao, G; Dominici, FP; Giani, JF; Toblli, JE | 1 |
| Anker, SD; Comin-Colet, J; Ertl, G; Filippatos, G; Komajda, M; Levesque, V; Mareev, V; McDonagh, T; Mori, C; Parkhomenko, A; Ponikowski, P; Roubert, B; Ruschitzka, F; Tavazzi, L; van Veldhuisen, DJ | 1 |
| Allocca, M; Danese, S; Fiorino, G | 1 |
| Anderson, B; Fazakerley, R; Garvican-Lewis, LA; Gore, CJ; Hughes, D; Lovell, G; Saunders, PU; Thompson, KG; Woods, A | 1 |
| Chainey, S; Cushway, T; Laass, MW; Straub, S; Virgin, G | 1 |
| Cornelius, C; Goldenberg, H; Haider, K; Praschberger, M; Scheiber-Mojdehkar, B; Schitegg, M; Sturm, B | 1 |
| Bach, M; Geisel, T; Röhrig, G; Schaefer, R; Schulz, RJ; Stein, J; Steinmetz, T; Virgin, G | 1 |
| Birgegård, G; Felder, M; Hedenus, M; Karlsson, T; Ludwig, H; Roubert, B; Rzychon, B | 1 |
| Keating, GM | 1 |
| Baker, S; Erber, W; Farmer, S; Ferrier, J; French, C; Hawkins, D; Higgins, AM; Hofmann, A; Keulenaer, BL; Litton, E; McMorrow, J; Olynyk, J; Richards, T; Towler, S; Webb, S | 1 |
| Gasche, C; Iqbal, T; Kulnigg-Dabsch, S; Sharma, N; Stein, J; Vel, S | 1 |
| Angerosa, M; Toblli, JE | 1 |
| Fuertes Martín, A; Inés Revuelta, S; Moralejo Alonso, L; Sánchez González, R; Ternavasio-de la Vega, HG | 1 |
| Anker, SD; Comín-Colet, J; Enjuanes-Grau, C; Gutzwiller, FS; Ponikowski, P; Rubio-Rodríguez, D; Rubio-Terrés, C | 1 |
| Anker, SD; Colet, JC; Dickstein, K; Filippatos, G; Ford, I; Gaudesius, G; Greenlaw, N; Lüscher, T; Macdougall, I; Mori, C; Ponikowski, P; von Eisenhart Rothe, B; Willenheimer, R | 1 |
| Češka, R | 1 |
| Borg, S; Hofmarcher, T | 1 |
| Alavian, KN; Ashek, A; Bozorgi, S; Busbridge, M; Cotroneo, E; Dubois, O; Wang, L; Wharton, J; Wilkins, MR; Zhao, L | 1 |
| Braitsch, M; Burckhardt, S; Dippon, U; Funk, F; Göttlicher, J; Kappler, A; Neiser, S; Philipp, E; Rentsch, D; Steininger, R; Weidler, PG; Wilhelm, M | 1 |
| Jamieson, A; Mattinson, A; Pelosi, AJ | 1 |
| Barrière, J; Bugat, R; Concas, VH; Duvillié, L; Huot-Marchand, P; Laribi, K; Luporsi, E; Morere, JF; Scotté, F; Toledano, A | 1 |
| Di Gennaro, F; Toblli, JE | 1 |
| Arneth, B; Bornstein, SR; Heigl, F; Hettich, R; Illigens, BM; Julius, U; Prophet, H; Ramlow, W; Schatz, U; Siegels, D; Siegert, G; Siepmann, T | 1 |
| Bridgeman, MB; Dalal, KS | 1 |
| Connor, JR; Nixon, AM; Perno, JR; Webb, B; Zhang, X | 1 |
| Borrás-Blasco, J; Boscá, M; Cortés, E; Cortes, X; Molés, JR | 1 |
| Anker, SD; Clevenger, B; Collier, T; Keidan, J; Kelly, JD; Klein, AA; Richards, T | 1 |
| Bemelman, WA; Borstlap, WAA; Buskens, CJ; C A Wientjes, CA; Consten, ECJ; de Castro, SMM; Dijkgraaf, MGW; Gerhards, MF; Heuff, G; Jansen, J; Kennelly, RP; Omloo, JM; Tanis, PJ; Tolboom, RC; Tuynman, JB; Tytgat, KMAJ; van der Ven, AWH; van der Zaag, E; van Geloven, N; van Wagensveld, BA; van Westreenen, HL; Winter, DC | 1 |
| de Teresa, E; García-Pinilla, JM; Gómez-Doblas, JJ; González-Cruces, N; Morcillo-Hidalgo, L; Robledo-Carmona, J; Robles-Mezcua, A; Ruiz-Salas, A | 1 |
| ÀngelRuíz, M; Calleja, JL; Calvet, X; Cucala, M; Delgado, S; Figuerola, A; Gené, E; Mearin, F; Villoria, A | 1 |
| Bassetti, C; Baumann, C; Gyr, T; Hübner, A; Krafft, A; Manconi, M; Schneider, J; Werth, E | 1 |
| Koch, TA; Okam, MM; Tran, MH | 1 |
| Brunetta, DM; De Santis, GC; Garcia, JH; Kaufman, J; Mesquita, DF; Souza, FN | 1 |
| Fajt, ML; Montandon, SV; Petrov, AA | 1 |
| Marmifero, M; Meregaglia, M; Rognoni, C; Tarricone, R; Venturini, S | 1 |
| Calleja, JL; Cucala, M; del Val, A; Delgado, S; Hervás, A; Larraona, JL; Mearin, F; Terán, Á | 1 |
| Bizot, P; Chassier, C; Chaudet, A; Lasocki, S; Rineau, E | 1 |
| Froessler, B; Hodyl, NA; Murphy, EM; Palm, P; Singh, R; Weber, I | 1 |
| Cançado, RD; Frugis, MO; Sobrado, CW; Sobrado, LF; Sobrado, MF | 1 |
| Bhatla, N; Kachhawa, G; Kriplani, A; Mahey, R; Mogili, KD; Saxena, R | 1 |
| Crumbliss, AL; Gupta, A; Pratt, RD | 1 |
| Anker, SD; Comin-Colet, J; Cooper, TJ; Dickstein, K; Filippatos, G; Johnson, P; Lainscak, M; Lüscher, TF; Mori, C; Ponikowski, P | 1 |
| Acornley, A; Alexander, D; Frew, N; Hood, J | 1 |
| Bajador, E; Bocos, JM; Castaño, C; Chaparro, M; García-Erce, JA; García-López, S; Gisbert, JP; Gomollón, F | 1 |
| Fell, LH; Fliser, D; Heine, GH; Rotter, B; Seiler-Mußler, S; Sellier, AB; Sester, M; Winter, P; Zawada, AM | 1 |
| Aparicio, R; Bernabeu-Wittel, M; Melero-Bascones, M; Monte-Secades, R; Murcia-Zaragoza, J; Ollero-Baturone, M; Rincón-Gómez, M; Romero, M; Rosso, CM; Ruiz-Cantero, A | 1 |
| Girrbach, G | 1 |
| Macdougall, IC | 2 |
| Coyne, DW; Daloul, R; Pandey, R | 1 |
| Gearry, RB | 1 |
| Ghaly, S | 1 |
| Bansal, SS; Bock, AH; Carrera, F; Cronin, M; Eckardt, KU; Gaillard, CA; Larroque, S; Macdougall, IC; Meier, Y; Roger, SD; Van Wyck, DB | 1 |
| Bernard, R; Breymann, C; Dudenhausen, J; Mezzacasa, A; Milman, N | 1 |
| Agrogiannis, I; Drakou, A; Margeli, A; Papassotiriou, I; Poziopoulos, C; Theodorakopoulou, S; Vlahakos, DV | 1 |
| Bäumer, N; Gallitz, I; Kuhlmann, T; Lofruthe, N; Müller-Tidow, C; Schulze, I; Steinbicker, AU; Traeger, L | 1 |
| Baru, AM; Bauersachs, J; Engeli, S; Flögel, U; Galy, B; Groos, S; Haddad, S; Heineke, J; Hentze, MW; Hirsch, V; Jordan, J; Kempf, T; Korf-Klingebiel, M; Reboll, MR; Renner, A; Rostami, F; Toischer, K; Wang, Y; Wollert, KC; Zimmermann, F | 1 |
| Auerbach, M; Muñoz, M | 1 |
| Al-Badri, R; Gray, Z; Ingram, E; Khalafallah, AA; Khelgi, V; Kirkby, BE; Kirkby, BP; Robertson, IK; Robinson, E; Yan, C | 1 |
| Lopes, AI; Maltez, C; Valério de Azevedo, S | 1 |
| Al-Khaffaf, A; Capelli, S; Melli, C; Polese, F; Salvadori, U; Sandri, M; Simeoni, M | 1 |
| Baker, S; De Keulenaer, B; Erber, WN; Farmer, S; Ferrier, J; French, C; Gummer, J; Hawkins, D; Higgins, A; Hofmann, A; Litton, E; McMorrow, J; Olynyk, JK; Richards, T; Towler, S; Trengove, R; Webb, S | 1 |
| Bruder, O; Hambrecht, R; Hochadel, M; Maeder, MT; Michel, S; Pauschinger, M; Pfister, O; Remppis, BA; Senges, J; Strasser, R; von Scheidt, W; Wienbergen, H | 1 |
| Cook, JC; Patterson, JH; Rodgers, JE; Tran, RH | 1 |
| Adix, L; Buchanan, GR; McCavit, TL; Powers, JM; Shamoun, M | 1 |
| Amrein, K; Drexler, C; Lindenau, I; Macher, S; Sareban, N; Schlenke, P | 1 |
| Allen, RP; Cho, YW; Earley, CJ | 2 |
| Bansal, SS; Huang, L; Kent, AB; Lee, D; Macdougall, IC; MacGinley, R; McMahon, LP; Roberts, MA; Troster, SM | 1 |
| Bager, P; Dahlerup, JF; Hvas, CL | 1 |
| Berger, SP; Daha, MR; de Vlaam, TP; Franssen, CF; Gaillard, CA; Gaya da Costa, M; Hempel, JC; Poppelaars, F; Seelen, MA | 1 |
| Braithwaite, V; Effenberger, M; Finkenstedt, A; Griesmacher, A; Moschen, A; Schaefer, B; Sulzbacher, I; Tilg, H; Viveiros, A; Vogel, W; Würtinger, P; Zoller, H | 1 |
| Plate, A | 1 |
| Bugat, R; Duvillié, L; Espié, M; Luporsi, E; Perot, S; Pithois Merli, I; Scotté, F; Spaeth, D; Toledano, A | 1 |
| Bakker, SJ; Eisenga, MF; Gaillard, CA | 1 |
| Acheson, AG; Brookes, MJ; Keeler, BD; Ng, O; Padmanabhan, H; Simpson, JA | 1 |
| Borobia, AM; García-Erce, JA; Gómez-Ramírez, S; Muñoz, M; Muñoz-Romo, R; Pavía, J; Quintana-Díaz, M | 1 |
| Mantadakis, E; Roganovic, J | 1 |
| Bayes-Genis, A; de Antonio, M; Domingo, M; González, B; Lupón, J; Moliner, P; Núñez, R; Pacho, C; Santesmases, J; Tor, J; Vela, E | 1 |
| Atiqi, R; Heijboer, AC; Hesselink, DA; Hoorn, EJ; Sari, V; van Gelder, T | 1 |
| Bock, AH; Carrera, F; Cronin, M; Eckardt, KU; Gaillard, CA; Larroque, S; Macdougall, IC; Meier, Y; Roger, SD; Van Wyck, DB | 1 |
| Auerbach, M; Macdougall, I | 1 |
| Glodny, B; Schaefer, B; Zoller, H | 1 |
| Anker, SD; Arutyunov, GP; Comin-Colet, J; Filippatos, G; Kirwan, BA; Lüscher, TF; Mori, C; Motro, M; Pocock, SJ; Ponikowski, P; Roubert, B; Ruschitzka, F; van Veldhuisen, DJ | 1 |
| Hubert, L; Lasocki, S; Rineau, E; Samson, E; Stoyanov, A | 1 |
| An, JY; Bae, JM; Choi, MG; Eom, BW; Han, M; Jeong, O; Jung, MR; Kim, BS; Kim, HI; Kim, S; Kim, Y; Kim, YW; Kwon, OK; Lee, HJ; Lee, IS; Lee, JH; Nam, BH; Noh, SH; Park, YK; Ryu, KW; Ryu, SY; Sohn, TS; Suh, YS; Yang, H; Yang, HK; Yoo, MW; Yook, JH; Yoon, HM; Yu, W | 1 |
| Mezzacasa, A; Oertel, W; Roubert, B; Trenkwalder, C; Virgin, G; Winkelmann, J | 1 |
| Borgeaud, M; Perrier, A | 1 |
| Anabitarte, P; Gstrein, C; Meyer, M | 1 |
| Grigoriadis, G; Low, MS | 1 |
| Boccia, S; Di Pietro, ML; Fabrizio, L; Favaretti, C; Gasbarrini, A; Kheiraoui, F; Poscia, A; Proli, EM; Scaldaferri, F; Stojanovic, J; Volpe, M | 1 |
| Boccia, S; Canarecci, S; Ciancarella, G; Collamati, A; de Waure, C; Gasbarrini, A; Kheiraoui, F; Milovanovic, S; Poscia, A; Scaldaferri, F; Schiavoni, E | 1 |
| Gaynor, E; Howarth, L; Rodrigues, A; Tan, MLN; Thornton, G; Windscheif, PM | 1 |
| Grivell, RM; Grzeskowiak, LE; Mol, BW; Qassim, A | 1 |
| Eichner, D; Garvican-Lewis, LA; Gore, CJ; Govus, AD; Hughes, D; Lovell, G; Schumacher, YO; Vuong, VL | 1 |
| Breymann, C; Honegger, C; Hösli, I; Surbek, D | 1 |
| Borrelli, S; Conte, G; De Nicola, L; Garofalo, C; Liberti, ME; Minutolo, R; Sagliocca, A | 1 |
| Li, T; Yu, Z | 1 |
| Kim, YW; Yang, H | 1 |
| Katz, SD | 1 |
| Gandhi, K; Hokabaj, S; Mishra, V; Roy, P; Shah, KN | 1 |
| Muduma, G; Pollock, RF | 4 |
| Stewart Coats, AJ | 1 |
| Huang, LL; Kent, AB; Lee, D; Macdougall, IC; McMahon, LP; Roberts, MA; Troster, SM | 1 |
| Angerosa, M; Cao, G; Rico, L; Toblli, JE | 1 |
| Singler, K | 1 |
| Epstein, J; Fell, JME; Goto, E; Korologou-Linden, R; Papadopoulos, M; Patel, D; Soondrum, K | 1 |
| Asaad, S; Econs, M; Klein, K; Rubin, JE | 1 |
| Ara, R; Bader, GN; Naqash, A | 1 |
| Castberg, FC; Clasen-Linde, E; Hempel, C; Hviid, L; Kurtzhals, JAL; Maretty, L; Staalsoe, T | 1 |
| Ching, A; Cushway, T; Hadi, FA; Lam, CSP; Lee, KY; Li, R; Lim, SL; Loh, SY; Richards, AM; Tai, BC; Wong, RC; Yeo, PSD; Yeo, TJ; Yin, FF | 1 |
| Aggarwal, R; Choudhary, S; Gandhi, K; Mishra, V; Roy, P; Sokabaj, S | 1 |
| Ikuta, K; Kawabata, Y; Shimura, A; Terauchi, M; Yoshii, K | 1 |
| Adkinson, NF; Auerbach, M; Bernard, KE; Chertow, GM; Kaper, RF; Krop, JS; Macdougall, IC; Strauss, WE | 1 |
| Catarinolo, M; Enzmann, H; Fütterer, S; Langguth, P; Schlösser, C; Schnorr, J; Spicher, K | 1 |
| Arkkila, P; Färkkilä, M; Haapamäki, J; Kangaspunta, M | 1 |
| Cutts, BA; Gilmartin, CE; Hoang, T; Leung, L | 1 |
| Abergel, A; Aumaitre, O; Bagel, S; Boisgard, S; Delpeuch, A; Ruivard, M; Sautou, V | 1 |
| Scott, LJ | 1 |
| Eichner, D; Garvican-Lewis, LA; Gore, CJ; Govus, AD; Hughes, D; Jung, G; Lovell, G; Nemeth, E; Peeling, P; Vuong, VL | 1 |
| Kim, HJ; Kim, SK; Seo, WY; Yoo, JJ | 1 |
| Almenar, L; Amiguet, M; Bayés-Genís, A; Bodí, V; Cardells, I; Chorro, FJ; de la Espriella-Juan, R; Fácila, L; García-Blas, S; González, J; Llàcer, P; López-Lereu, MP; López-Vilella, R; Miñana, G; Monmeneu, JV; Montagud, V; Núñez, J; Palau, P; Sanchis, J; Serrano, A; Valero, E | 1 |
| Dekker, G; Froessler, B; Gajic, T; Hodyl, NA | 2 |
| Brandenburg, V; Heine, GH; Marx, N; Sandstede, L; Stöhr, R | 1 |
| Azouza, W; Boustany, R; Chanet, B; Coussirou, J; De Crozals, F; Debourdeau, A; Debourdeau, P; Jean, C; Stancu, A | 1 |
| Alonso-Gonzalez, R; Beghetti, M; Blanche, C; Dimopoulos, K; Kempny, A; Price, L; Swan, L; Uribarri, A; Wort, SJ | 1 |
| Ascanio, M; Darbà, J | 1 |
| Aksan, A; Dignass, A; Klemm, W; Nip, K; Stein, J; Weber-Mangal, S | 1 |
| Mundy, LM; Wohlfeil, S | 1 |
| Auerbach, M; Chertow, GM; Franklin Adkinson, N; Kaper, RF; Krop, JS; Macdougall, IC; Strauss, WE | 1 |
| Choorapoikayil, S; Füllenbach, C; Glaser, P; Meybohm, P; Triphaus, C; Zacharowski, K; Ziebart, A | 1 |
| Basora, M; Coca, M; Lozano, L; Pereira, A; Tió, M | 1 |
| Hanashi, H; Hirai, K; Ikuta, K; Matsuyama, Y; Momoeda, M; Ota, Y; Shimura, A; Terauchi, M | 1 |
| Lichtenstein, GR; Onken, JE | 1 |
| Biboulet, P; Bringuier, S; Capdevila, X; Dangelser, G; Loupec, T; Maissiat, G; Pencole, M; Smilevitch, P; Thuile, C | 1 |
| Cho, YK; Jun, JK; Kim, A; Kim, MY; Kim, YJ; Lee, JJ; Lee, KY; Lee, Y; Shim, JY; Shin, JC; Song, TB | 1 |
| Ikuta, K; Ito, H; Masaki, S; Suzuki, Y; Takahashi, K; Terauchi, M | 1 |
| Dasseni, N; Dinatolo, E; Lombardi, C; Metra, M; von Haehling, S | 1 |
| Bakker, SJL; Diepenbroek, A; Eisenga, MF; Franssen, CFM; Gaillard, CAJM; Hofman, JMG; Nolte, IM; van Dam, B; Westerhuis, R | 1 |
| Ballester-Clau, R; Cucala-Ramos, M; López-Barroso, L; Planella de Rubinat, M; Reñé-Espinet, JM; Torres Vicente, G; Voltà-Pardo, T | 1 |
| Abdelazim, IA; Nusair, B; Svetlana, S; Zhurabekova, G | 1 |
| Borlaug, BA; Dezortova, M; Hajek, M; Hlavata, K; Kautzner, J; Melenovsky, V; Petrak, J; Sedivy, P | 1 |
| Birnie, E; Mulder, MB; van den Hoek, HL; van Tilburg, AJP; Westerman, EM | 1 |
| Cabrales Alin, D; Hofmarcher, T; Linde, C | 1 |
| Brizuela, NO; García, EH; Guzmán, DC; Herrera, MO; Jiménez, FT; Mejía, GB; Olguín, HJ; Peraza, AV | 1 |
| García-Erce, JA; Lorente Aznar, T; Rivilla Marugán, L | 1 |
| Allen, JC; Chuang, A; Dennis, A; Falloon, P; Gray, Z; Hanna, F; Hyppa, A; Khalafallah, AA; Kwok, C; Mathew, R; Pavlov, T; Wilson, E; Yan, C | 1 |
| Chertow, GM; Kaper, R; Krop, J; Macdougall, IC; Strauss, W; Wolf, M | 1 |
| Bocuk, D; Ehlken, B; Gohlke, A; Nathell, L; Toussi, M; Wohlfeil, S | 2 |
| Anker, SD; Ebner, N; Evertz, R; Ponikowski, P; von Haehling, S | 1 |
| Caló, N; Laso-Morales, MJ; Pontes, C; Valle-Beltran, A; Vallejo-Tarrat, A; Vives, R | 1 |
| Abreu Padín, C; Castro Ramos, JC; Gómez Peralta, F; Gómez Rodríguez, S | 1 |
| Bhatla, N; Jose, A; Kalaivani, M; Kriplani, A; Mahey, R; Saxena, R; Sharma, JB | 1 |
| Chung, YJ; Lakhal-Littleton, S; Loonat, AA; Luo, A; Park, KC; Robbins, PA; Swietach, P | 1 |
| Bedouch, P; Romanet, T; Zaoui, P | 1 |
| Fava, C; Piepoli, M; Villani, GQ | 1 |
| Diebold, M; Kistler, AD | 1 |
| Kim, T; Lee, ES; Lee, JJ; Lee, KH; Lee, S; Ryu, KJ | 1 |
| Schaffalitzky de Muckadell, P; Strom, CC | 1 |
| El-Zaatari, MS; Hassan-Smith, ZK; Reddy-Kolanu, V | 1 |
| Bronswijk, M; Christiaens, P; Van Olmen, A | 1 |
| Amrein, K; Drexler, C; Holter, M; Lindenau, I; Macher, S; Moritz, M; Pieber, TR; Schlenke, P; Stojakovic, T | 1 |
| Bourguignon, S; Caranhac, G; Champs, FO; Cohen-Solal, A; Faller, M; Levesque, K; Moutier, H | 1 |
| Falk, V; Hegemann, I; Hofmann, A; Kaserer, A; Maisano, F; Schoenrath, F; Seifert, B; Spahn, DR; Spahn, GH; Stein, P; Theusinger, OM | 1 |
| Abu-Own, H; Anker, SD; Colet, JC; Filippatos, G; Jouhra, F; Mori, C; Okonko, DO; Ponikowski, P; Suki, C | 1 |
| Aksan, A; Dignass, A; Stein, J | 2 |
| Crowley, CM; Desmond, J; Imcha, M; McMahon, G | 2 |
| Detlie, TE; Finnes, E; Jahnsen, J; Jahnsen, ME; Lindstrøm, JC; Moum, B; Zoller, H | 1 |
| Hu, F; Ji, C; Li, S; Liu, B; Long, J; Ming, M; Ren, H; Wang, F; Xu, Z; Yang, B; Yang, X; Zhu, Z | 1 |
| Musgrove, J; Wolf, M | 1 |
| Detlie, TE; Jahnsen, J | 1 |
| Andreucci, M; Calimeri, S; Cernaro, V; Comi, A; Coppolino, G; Cosentino, S; Donato, C; Leonardi, G; Lucia, CM; Michael, A; Nicotera, R; Provenzano, M | 1 |
| Edmonston, D; Wolf, M | 1 |
| Cho, H; Koo, CH; Ryu, JH; Shin, HJ | 1 |
| Dauw, J; Dupont, M; Herbots, L; Martens, P; Mullens, W; Somers, F; Timmermans, P; Verwerft, J | 1 |
| Gerzeli, S; Rognoni, C | 1 |
| Hamano, T | 1 |
| Altermatt, P; Doucerain, C; Dürrenberger, F; Flace, A; Manolova, V; Nyffenegger, N; Sundstrom, H; Varol, A | 1 |
| Brambilla, AM; Cappellini, MD; Consonni, D; Mantovan, G; Materia, M; Migone De Amicis, M; Montano, N; Motta, I; Porzio, M | 1 |
| Hinds, R; Hong, MH; Singh, H | 1 |
| Anker, SD; Dorobantu, M; Drozdz, J; Fabien, V; Filippatos, G; Haboubi, T; Jankowska, EA; Keren, A; Khintibidze, I; Kirwan, BA; Kragten, H; Martinez, FA; McDonagh, T; Metra, M; Milicic, D; Nicolau, JC; Ohlsson, M; Parhomenko, A; Pascual-Figal, DA; Ponikowski, P; Ruschitzka, F; Sim, D; Skouri, H; van der Meer, P | 1 |
| Amarelo, A; Capela, A; Coelho, H; Costa, T; Cunha, Â; Custódio, S; Dias, E; Dias, M; Joaquim, A; Leão, I; Macedo, A; Marinho, J; Moreira Pinto, A | 1 |
| Amarnani, R; Javaid, MK; Travis, S | 1 |
| Ding, Y; Li, C; Li, X; Liu, J; Palmen, M; Roubert, B; Wu, M; Zhang, H; Zhu, X | 1 |
| Kiechl-Kohlendorfer, U; Mueller, T; Posod, A; Schaefer, B; Zoller, H | 1 |
| Busti, F; Girelli, D; Marchi, G | 1 |
| Achebe, M; Brandenburg, V; Carpenter, TO; Econs, MJ; Imel, EA; Peacock, M; Rubin, J; Thomsen, LL; Weber, T; Wolf, M; Zoller, H | 1 |
| Loughnane, F; Muduma, G; Pollock, RF | 1 |
| Almenar, L; Amiguet, M; Bayés-Genís, A; Bodí, V; Cardells, I; Chorro, FJ; Comín-Colet, J; de la Espriella-Juan, R; Fácila, L; García-Blas, S; González, J; Górriz, JL; Llàcer, P; López-Lereu, MP; López-Vilella, R; Lupón, J; Miñana, G; Monmeneu, JV; Montagud, V; Navarro, J; Núñez, J; Palau, P; Sanchis, J; Serrano, A; Valero, E | 1 |
| Caccamo, G; Di Franco, A; Giallauria, F; Nugara, C; Sarullo, FM; Sarullo, S; Vitale, G; Vitale, S | 1 |
| Calò, LA; Carraro, G; Cattarin, L; Gobbi, L; Qassim, L; Rigato, M; Rossi, B; Scaparrotta, G | 1 |
| Albanesi, M; Caiaffa, MF; Di Bona, D; Di Girolamo, A; Loconte, F; Macchia, L | 1 |
| Brandenburg, V; Heine, GH; Marx, N; Stöhr, R | 1 |
| Aczél, S; Bilz, S; Brändle, M; Frei, N; Räss, A; Schoeb, M | 1 |
| Herrera, A; Mateo-Agudo, J; Muñoz, M; Pinilla-Gracia, C | 1 |
| Akdogan, N; Bostan, E; Karaduman, A; Ozdemir, DA; Yalcin, HB | 1 |
| Amrein, K; Drexler, C; Herster, C; Holter, M; Macher, S; Matzhold, EM; Moritz, M; Pieber, TR; Schlenke, P; Stojakovic, T | 1 |
| Adatto, M; Borradori, L; Cazzaniga, S; Dietrich, N; Feldmeyer, L; Heidemeyer, K; Raeber, I; Seyed Jafari, SM; Yawalkar, N | 1 |
| Aarts, EO; Berends, FJ; Boerboom, A; de Boer, H; de Bruyn Kops, M; de Raaff, C; Janssen, IMC; Schijns, W; van Laarhoven, CJHM; van Wagensveld, B | 1 |
| Ortez-Toro, JJ; Peteiro-Miranda, CM; Román-Gimeno, S; Sanz-Martín, B; Urdaniz-Borque, R | 1 |
| Luan-Erfe, BM; Sweitzer, B; Yilmaz, M | 1 |
| Jang, JH; Jung, CW; Kim, K; Kim, SJ; Kim, WS; Kim, Y; Lee, J; Lee, SH; Park, S | 1 |
| Fang, W; Garg, M; Kenny, R; McMahon, LP; Rizvi, QU | 1 |
| Álvarez-Pérez, JM; Berrocal-Gil, P; Borraz-Ordás, C; Comabella, R; Comín-Colet, J; Fernández-Cañadas, JM; Ferre, C; Herrero-Puente, P; Jacob, J; Llopis-García, G; Llorens, P; López-Díez, P; Martín-Sánchez, FJ; Martínez-Gimeno, JL; Mercado, A; Miró, Ò; Pérez-Durá, MJ; Richard-Espiga, F; Roset, A; Valero-Domènech, A | 1 |
| Bafadhel, M; Baskerville, R; Frise, MC; McGahey, A; Nickol, AH; Petousi, N; Robbins, PA; Santer, P; Talbot, NP | 1 |
| Beverina, I; Brando, B; Garcia-Erce, JA; Jericó, C; Melli, C; Quintana-Diaz, M; Recasens, V; Rondinelli, MB; Salvadori, U | 1 |
| Farland, MZ; Khoury, A; Pagan, KA | 1 |
| Böhm, M; Brandenburg, VM; D'Amelio, R; Emrich, IE; Fliser, D; Heine, GH; Kaddu-Mulindwa, D; Lizzi, F; Seiler-Mussler, S; Siegel, JD; Ukena, C; Wagenpfeil, S | 1 |
| Allard, M; Bernimoulin, M; Guidard, C; Ozsahin, H; Schaeppi, M; van den Ouweland, F | 1 |
| Cai, X; David, V; Frazier, R; Hodakowski, A; Isakova, T; Lee, J; Mehta, R; Stein, B; Wolf, M; Zakarija, A | 1 |
| Aiello, A; Berto, P; Conti, P; Panichi, V; Rosati, A | 1 |
| Akdeniz, B; Arici, AM; Gelal, A; Kumral, Z | 1 |
| Asma, S; Aytan, P; Boğa, C; Büyükkurt, N; Gereklioğlu, Ç; Kasar, M; Korur, A; Özdoğu, H; Solmaz, S; Tanrikulu, FP; Yeral, M | 1 |
| Fisher, S; Jonker, L | 1 |
| DelRosso, LM; Ferri, R; Picchietti, DL | 1 |
| Artoni, A; Capecchi, M; Cappellini, MD; La Marca, S; Motta, I; Scaramellini, N | 1 |
| Andina, N; da Costa, BR; Erlanger, TE; Fontana, S; Hincapié, CA; Jüni, P; Keller, P; Lämmle, B; Niederhauser, C; von Känel, R | 1 |
| Allen, RP; Choi, SJ; Joo, EY; Park, HR | 1 |
| Berdot, S; Loustalot, MC; Perrin, G; Pouchot, J; Sabatier, B; Touchard, J | 1 |
| Hengartner, H; Mattiello, V; Renella, R; Schmugge, M; von der Weid, N | 1 |
| Buyuk, GN; Engin-Ustun, Y; Keskin, HL; Kilickiran, H; Oskovi-Kaplan, ZA; Ozyer, S | 1 |
| Chui, F; Dashwood, A; Hay, K; Laher, S; Vale, C; Wong, YW | 1 |
| Cepeda, JM; Comín-Colet, J; Delgado, JF; Garcia-Casanovas, A; García-García, JÁ; González-Domínguez, A; González-Franco, Á; Jiménez Merino, S; Oliva, J | 1 |
| Beverina, I; Brando, B; Scalvini, R | 1 |
| Kennedy, NA; Schaefer, B; Tilg, H; Tobiasch, M; Viveiros, A; Wolf, M; Zoller, H | 1 |
| Anker, SD; Butler, J; Cohen-Solal, A; Comin-Colet, J; Danchin, N; Dargie, HJ; Doehner, W; Dorobantu, M; Drozdz, J; Fabien, V; Filippatos, G; Friede, T; Göhring, UM; Jankowska, EA; Jensen, KH; Keren, A; Khintibidze, I; Kirwan, BA; Kragten, H; Lewis, BS; Martinez, FA; McDonagh, T; Metra, M; Milicic, D; Motro, M; Nicolau, JC; Ohlsson, M; Parkhomenko, A; Pascual-Figal, DA; Pocock, S; Ponikowski, P; Ruschitzka, F; Sim, D; Skouri, H; van der Meer, P; von Haehling, S | 1 |
| Barclay, A; Curtis, L; Duncan, H; Fraser, S; Hansen, R; McGuckin, C; Nair, M; Russell, RK; Sasankan, N; Shannon, C | 1 |
| Abdulla, S; Asilia, P; Daubenberger, C; Glass, TR; Issa, A; Kuemmerle, A; Lweno, O; Meyer-Monard, S; Mswata, S; Mwebi, KD; Schmidlin, S; Simon, B; Tanner, M; Vanobberghen, F | 1 |
| Balla, S; Bianco, C; Faisaluddin, M; Kheiri, B; Osman, M; Syed, M | 1 |
| Darbandi, MA; Razlighi, MR; Tabasi, O | 1 |
| Bennett, A; Chunilal, S; Coughlin, E; Dev, A; Gilbertson, M; Indran, T; Opat, S; Pasricha, SR; van Dam, M | 1 |
| Ganz, T; Goodnough, LT; Kalantar-Zadeh, K; Levine, MA; Seid, MH; Trumbo, H | 1 |
| Akobeng, AK; Allen, P; Engineer, J; Gordon, M; Hoque, S; Iheozor-Ejiofor, Z; Iqbal, T; Sinopoulou, V | 1 |
| Lam, CSP; Teramoto, K; Tromp, J | 1 |
| Doehner, W; Khan, MS; Stewart Coats, AJ; Usman, MS; von Haehling, S | 1 |
| Patrono, C; Volpe, M | 1 |
| Antonioli, L; Baiano Svizzero, G; Bellini, M; Bertani, L; Blandizzi, C; Coppini, F; de Bortoli, N; Marchi, S; Tricò, D; Zanzi, F | 1 |
| Efe, O; García, JDC; Mount, DB; Sheridan, AM | 1 |
| Auerbach, M; Farmer, SL; Frank, SM; Hardy, JF; Javidroozi, M; Leahy, MF; Meier, J; Ozawa, S; Shander, A | 1 |
| Bernhardt, MB; Kirk, SE; Mahoney, DH; Powers, JM; Scheurer, ME | 1 |
| Borrelli, O; Chadokufa, S; Cococcioni, L; El-Khouly, S; Kiparissi, F; McCartney, S; Pensabene, L; Saliakellis, E | 1 |
| Di Lenarda, A; Nesti, U; Sciatti, E | 1 |
| Allinovi, M; Bagalà, A; Ballo, P; Bellelli, S; Cirillo, L; Dallari, LA; Dattolo, PC; Di Marcantonio, E; Ferro, G; Somma, C | 1 |
| DeFilippis, EM; Van Spall, HGC | 1 |
| Aloni, A; Beverina, I; Brando, B; Gatti, F; Varalli, L | 1 |
| Andrès, A; Assouline, B; Benoliel, A; Delhumeau, C; Favre, M; Legouis, D; Samii, K; Schiffer, E; Toso, C; Zamberg, I | 1 |
| Bokemeyer, B; Domènech, E; Howaldt, S; Martinez, N; Schmidt, C | 1 |
| Ambrosy, AP; Butler, J; De Pasquale, CG; Dugan, M; Ezekowitz, JA; Garg, J; Hernandez, AF; Leloudis, D; Lewis, GD; Mentz, RJ; Mundy, LM; O'Meara, E; Rockhold, FW; Samsky, MD; Troughton, RW; Wong, YW | 1 |
| Choi, YJ; Go, DY; Jang, YK; Ko, EJ; Lee, SW; Shin, HW; You, HS | 1 |
| Gronda, E; Iacoviello, M; Palazzuoli, A | 1 |
| Anker, SD; Butler, J; Cohen-Solal, A; Comin-Colet, J; Danchin, N; Dargie, HJ; Doehner, W; Dorigotti, F; Dorobantu, M; Drozdz, J; Fabien, V; Filippatos, G; Friede, T; Jankowska, EA; Keren, A; Khintibidze, I; Kirwan, BA; Kosiborod, M; Kragten, H; Lewis, BS; Martinez, FA; McDonagh, T; Metra, M; Milicic, D; Motro, M; Nicolau, JC; Ohlsson, M; Parkhomenko, A; Pascual-Figal, DA; Pocock, S; Ponikowski, P; Ruschitzka, F; Sim, D; Skouri, H; van der Meer, P; von Haehling, S | 1 |
| Ikuta, K | 1 |
| Allen, RP; Bae, H; Cho, YW; Earley, CJ; Kim, KT | 1 |
| Amezcua-Prieto, C; Daru, J; Godolphin, PJ; Khan, KS; Nicolaides, M; Robinson, S; Rogozińska, E; Saborido, CM; Thangaratinam, S; Wang, R; Zamora, J | 1 |
| Bruckers, L; Dauw, J; Dendale, P; Dupont, M; Herbots, L; Martens, P; Mullens, W; Nijst, P; Tang, WHW; Vandervoort, P | 1 |
| Coats, AJS; Davis, JA; Dorigotti, F; Jankowska, EA; McEwan, P; O'Sullivan, D; Ponikowski, P; Ramirez de Arellano, A; Rosano, G | 1 |
| Acheson, AG; Al-Hassi, HO; Brookes, MJ; Evstatiev, R; Gasche, C; Jambrich, M; Keeler, B; Khare, V; Mangalika, M; Ng, O; Phipps, O; Worton, N | 1 |
| Jankowska, EA; Leszek, P; Mackiewicz, U; Mączewski, M; Oknińska, M; Paterek, A; Ponikowski, P | 1 |
| Khoo, PWR; McGrath, KH | 1 |
| Gupte, SA; Jangam, SM; Mudholkar, AS; Shah, AS; Venkataraman, G | 1 |
| Clarke, NA; Elliott, AD; Emami, M; Gallagher, C; Hanna-Rivero, N; Lau, DH; Lyrtzis, E; Mishima, RS; Roberts-Thomson, KC; Sanders, P; Stokes, MB; Tu, SJ; Wlochowicz, D; Wong, CX | 1 |
| Abdullah, MAJ; AbuMousa, R; Adel, AA; Aldapt, MB; Basha, A; Chandra, P; Ekeibed, Y; Hamad, A; Hussein, RM; Ibrahim, MIM; Mahfouz, A; Omar, NE; Shwaylia, HM; Yassin, MA | 1 |
| Bielesz, B; Gabriel, M; Gleiss, A; Hörl, WH; Lorenz, M; Monteforte, R; Prikoszovich, T; Sunder-Plassmann, G; Wolzt, M | 1 |
| Connolly, M; Lim, CK; Mirkazemi, C | 1 |
| Baldus, S; Dumitrescu, D; Gerhardt, F; Hellmich, M; Kramer, T; Natsina, K; Rosenkranz, S; Ten Freyhaus, H; Viethen, T; Wissmüller, M | 1 |
| Allen, RP; Chen, ML; DelRosso, LM; Ferri, R; Kapoor, V; Mogavero, MP; Picchietti, DL | 1 |
| Donato, AA; Green, J | 1 |
| Blackman, N; Boccia, R; Gilreath, JA; Henry, DH; Krupa, A; Makharadze, T | 1 |
| Bisbe, E; Carol-Boeris, F; García-Erce, JA; Laso-Morales, MJ; Martínez-López, F; Muñoz, M; Pontes-García, C; Vives, R | 1 |
| Gupte, SA; Shah, AS; Venkataraman, G | 1 |
| Ataíde, R; Biselele, K; Braat, S; Chinkhumba, J; Harding, R; Larson, L; Moya, E; Mwangi, MN; Mzembe, G; Pasricha, SR; Phiri, KS; Robberstad, B; Rogerson, S; Simpson, J; Stones, W | 1 |
| Schaefer, B; Wolf, M; Zoller, H | 1 |
| Barber, VS; Chester-Jones, M; Drakesmith, H; Dutton, SJ; Frise, MC; Griffith, DM; James, T; Marian, IR; McKechnie, SR; Robbins, PA; Shah, A; Singleton, J; Stanworth, SJ; Walsh, TS; Wray, K; Young, JD | 1 |
| Almenar Bonet, L; Arenas Martín, P; Calvo Asensio, M; Donoso Trenado, V; Ezzitouny, M; Guerrero Cervera, B; Jover-Pastor, P; López-Vilella, R; Lozano-Edo, S; Martinez Dolz, L; Martínez-Solé, J; Sánchez Martínez, JC; Sánchez-Lázaro, I; Sorolla Romero, J | 1 |
| Alexiadou, S; Fotoulaki, M; Makis, A; Mantadakis, E; Ntoumpara, M; Panagopoulou, P; Papazoglou, A; Tragiannidis, A | 1 |
| Casà, A; Crispino, F; Grova, M; Macaluso, FS; Maida, M; Mannino, M; Orlando, A; Renna, S; Rizzuto, G | 1 |
| Bernal, L; Gutiérrez Casbas, A; Madero Velázquez, L; Muñoz Pérez, R; Orts, B; Rodríguez, A; Sempere, L | 1 |
| Maniar, AR; Maniar, RN; Mishra, A; Sanghavi, N | 1 |
| Arjona Berral, JE; Baquero Úbeda, JL; Casellas Caro, M; Cerezales, M; Cuervo, J; García-Erce, JA; Gredilla Díaz, E; Hidalgo, MJC; Jiménez Merino, S; Martín Bayón, I; Muñoz Solano, A; Nicolás Picó, J; Ruano Encinar, M; Torras Boatella, MG | 1 |
| Anker, SD; Butler, J; Coats, AJS; Comin-Colet, J; Dorigotti, F; Fabien, V; Filippatos, GS; Friede, T; Goehring, UM; Jankowska, EA; Khan, MS; Metra, M; Piña, IL; Ponikowski, P; Rosano, G; Van Veldhuisen, DJ | 2 |
| Almenar, L; Bayés-Genís, A; Bodí, V; Cardells, I; Chorro, FJ; de la Espriella, R; Del Canto, I; Fácila, L; Llàcer, P; López-Lereu, MP; López-Vilella, R; Maceira, AM; Miñana, G; Monmeneu, JV; Moratal, D; Núñez, J; Palau, P; Sanchis, J; Santas, E | 1 |
| Bertrand, PB; Dauw, J; Dupont, M; Martens, P; Mullens, W; Nijst, P; Tang, WHW | 1 |
| Admetlló, M; Alvarado, M; Barreiro, E; Duran-Jordà, X; Echeverría-Esnal, D; Gea, J; Martín-Ontiyuelo, C; Rodó-Pin, A; Rodríguez-Chiaradía, DA | 1 |
| Carlin, K; Fukasawa, S; Horslen, SP; Kaenkumchorn, TK; Rosete, BE; Wendel, D | 1 |
| Altuntaş, F; Bozan, E; Çakar, MK; Candır, BA; Dal, MS; İskender, D; Seçilmiş, S; Ulu, BU; Yaman, S; Yiğenoğlu, TN | 1 |
| Bayés-Genís, A; Cardells, I; de la Espriella, R; Górriz, JL; Lorenzo, M; Núñez, J | 1 |
| Fuyuno, Y; Harada, A; Matsuno, Y; Morisaki, S; Saiki, T; Suekane, H; Suzuki, T; Taniguchi, Y; Torisu, T; Umeno, J | 1 |
| Anker, SD; Butler, J; Dorigotti, F; Fabien, V; Filippatos, G; Jankowska, EA; Kirwan, BA; Macdougall, IC; Metra, M; Pagnesi, M; Ponikowski, P; Rosano, G; Ruschitzka, F; Tomasoni, D; van der Meer, P | 1 |
| Ahmed, FZ; Kalra, PA; Kalra, PR; Pollock, RF | 1 |
| Funk, GC; Grasmuk-Siegl, E; Scherrer, S; Urban, MH | 1 |
| Aboustate, N; Church, R; Dekker, GA; Froessler, B; Hodyl, NA; Kelly, TL; Palm, P; Schubert, KO | 1 |
| Aksan, A; Anand, S; Stein, J; Zepp, F | 1 |
| Boots, JMM; Quax, RAM | 1 |
| Chen, Y; Guo, X; Lai, B; Li, M; Luo, H; Ye, G; Zhong, Y | 1 |
| Amstad, G; Geiger, J; Heinzelmann, V; Montavon, C; Werlen, L | 1 |
| Comin-Colet, J; Doehner, W; Sindone, A | 1 |
| González Hidalgo, V; Morán López, JM | 1 |
| Heo, CY; Jeong, JH; Lee, S; Myung, Y; Park, JK | 1 |
| Campos Fernandes, A; Costa, E; Lucas, J; Robalo Nunes, A; Sequeira, R; Sousa, P; Subtil, A | 1 |
| Packer, M | 1 |
| Aguirre, C; Ceruelo, I; García, M; Palacios-Zabalza, I; Txintxurreta-Albizua, A | 1 |
| Aliu, A; Bertrams Maartens, IA; Bevers, N; Escher, H; Oudshoorn, A; Pierik, MJ; Raijmakers, M; Rezazadeh Ardabili, A; Rosias, P; Stapelbroek, J; Teklenburg, S; van de Feen, C; Van de Vijver, E; van Rheenen, PF; Vande Velde, S; Vreugdenhil, A; Winkens, B | 1 |
| Binnie, R; Cohen-Solal, A; Comin-Colet, J; de Arellano, AR; Dorigotti, F; Harrison, C; Jankowska, EA; Lewis, RD; Lund, LH; McEwan, P; Ohlsson, M; Pascual-Figal, DA; Ponikowski, P; von Haehling, S; Wächter, S | 1 |
| Aygün, A; Kaya, Y; Özbilen, M; Savrun, ŞT | 1 |
| Dogan, DY; Eveslage, M; Karst, U; Macke, M; Martens, S; Müller, JC; Olivier, RMR; Rauer, M; Schrader, L; Steinbicker, AU; Wagner, NM; Wempe, C; Zarbock, A | 1 |
| Anker, SD; Butler, J; Fabien, V; Farmakis, D; Filippatos, G; Jankowska, EA; Kirwan, BA; Macdougall, IC; Metra, M; Ponikowski, P; Rosano, G; Ruschitzka, F; van der Meer, P; Wächter, S | 1 |
| Schaefer, B; Wagner, S; Zoller, H | 1 |
| Bitton-Worms, K; Bolotin, G; Dann, EJ; Friedman, T; Glam, R; Makhoul, M; Tam, DY; Weis, A | 1 |
| García-Erce, JA; Payán-Pernía, S; Pérez-Simón, JA | 1 |
| Eisenga, MF | 1 |
| Anker, MS; Anker, SD; Filippatos, G | 1 |
| Hernandez, AF; Mentz, RJ | 1 |
58 review(s) available for acebutolol and ferric carboxymaltose
| Article | Year |
|---|---|
The role of iron supplementation during epoietin treatment for cancer-related anemia.
Topics: Administration, Oral; Anemia, Iron-Deficiency; Drug Administration Schedule; Erythropoiesis; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Iron Compounds; Iron-Dextran Complex; Iron, Dietary; Maltose; Neoplasms; Randomized Controlled Trials as Topic | 2009 |
Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Hematinics; Humans; Maltose; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Intravenous iron in inflammatory bowel disease.
Topics: Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Gluconates; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Injections, Intraventricular; Iron; Iron-Dextran Complex; Maltose; Treatment Outcome | 2009 |
The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose.
Topics: Animals; Escherichia coli; Ferric Compounds; Ferrous Compounds; Humans; Infusions, Intravenous; Injections; Iron; Kinetics; Liver; Maltose; Mice; Mutagens; Safety; Salmonella typhimurium; Thermodynamics | 2010 |
Anemia in heart failure: an overview of current concepts.
Topics: Anemia; Comorbidity; Darbepoetin alfa; Erythropoietin; Ferric Compounds; Heart Failure; Hematinics; Humans; Injections, Intravenous; Iron Compounds; Maltose; Prognosis; Risk Assessment; Risk Factors; United States | 2011 |
Clinical use of intravenous iron: administration, efficacy, and safety.
Topics: Ferric Compounds; Ferrosoferric Oxide; Humans; Injections, Intravenous; Iron; Iron-Dextran Complex; Magnetite Nanoparticles; Maltose; Treatment Outcome | 2010 |
When is high-dose intravenous iron repletion needed? Assessing new treatment options.
Topics: Anemia, Iron-Deficiency; Animals; Disaccharides; Dose-Response Relationship, Drug; Drug Administration Schedule; Ferric Compounds; Hemorrhage; Humans; Infusions, Intravenous; Iron; Iron Deficiencies; Maltose | 2011 |
Ferric carboxymaltose for the treatment of iron-deficiency anemia. [corrected].
Topics: Administration, Oral; Anemia, Iron-Deficiency; Clinical Trials as Topic; Ferric Compounds; Follow-Up Studies; Humans; Maltose; Mouth Mucosa; Randomized Controlled Trials as Topic | 2012 |
State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease.
Topics: Algorithms; Anemia, Iron-Deficiency; Clinical Trials as Topic; Diagnosis, Differential; Disaccharides; Dose-Response Relationship, Drug; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Iron Deficiencies; Maltose; Prevalence; Thrombocytosis; Thromboembolism | 2013 |
Use of intravenous iron supplementation in chronic kidney disease: an update.
Topics: Administration, Intravenous; Administration, Oral; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferrosoferric Oxide; Hematinics; Humans; Iron-Dextran Complex; Maltose; Renal Dialysis; Renal Insufficiency, Chronic | 2013 |
[Importance of the different i.v. iron generations for everyday medical practice].
Topics: Anemia, Iron-Deficiency; Disaccharides; Dose-Response Relationship, Drug; Drug Substitution; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Humans; Infusions, Intravenous; Iron-Dextran Complex; Maltose; Structure-Activity Relationship; Treatment Outcome | 2013 |
[Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
Topics: Administration, Oral; Anaphylaxis; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Humans; Infusions, Intravenous; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Oxidative Stress; Renal Dialysis | 2013 |
Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide.
Topics: Anemia, Iron-Deficiency; Animals; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Iron; Maltose | 2013 |
Update on intravenous iron choices.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferrosoferric Oxide; Hematinics; Homeostasis; Humans; Intestinal Absorption; Maltose; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
[Iron deficiency in chronic heart failure: from diagnosis to therapy].
Topics: Anemia, Iron-Deficiency; Comorbidity; Diagnosis, Differential; Drug Dosage Calculations; Exercise Tolerance; Ferric Compounds; Heart Failure; Hemoglobinometry; Humans; Infusions, Intravenous; Maltose; Quality of Life | 2014 |
Iron deficiency: the hidden miscreant in inflammatory bowel disease.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Clinical Trials as Topic; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Maltose; Quality of Life | 2014 |
Ferric carboxymaltose: a review of its use in iron deficiency.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Humans; Injections, Intravenous; Maltose | 2015 |
Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.
Topics: Anemia, Iron-Deficiency; Drug Delivery Systems; Ferric Compounds; Humans; Maltose | 2014 |
[Anaemia and iron deficiency in clinical practice:from cardiology to gastroenterology and beyond].
Topics: Anemia, Iron-Deficiency; Cardiology; Clinical Protocols; Female; Ferric Compounds; Gastroenterology; Heart Failure; Humans; Male; Maltose; Pilot Projects; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2014 |
Iron deficiency anemia treatment response to oral iron therapy: a pooled analysis of five randomized controlled trials.
Topics: Administration, Oral; Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Iron; Male; Maltose; Randomized Controlled Trials as Topic | 2016 |
Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials.
Topics: Administration, Intravenous; Chemistry, Pharmaceutical; Ferric Compounds; Hemoglobins; Humans; Iron Deficiencies; Maltose; Randomized Controlled Trials as Topic | 2016 |
Iron Treatment Strategies in Nondialysis CKD.
Topics: Administration, Intravenous; Administration, Oral; Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrous Compounds; Glucaric Acid; Hematinics; Hemoglobins; Humans; Iron Compounds; Maltose; Renal Insufficiency, Chronic; Severity of Illness Index; Transferrin | 2016 |
Iron Treatment Strategies in Dialysis-Dependent CKD.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Hemoglobins; Humans; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Renal Dialysis; Transferrin | 2016 |
Evolving therapies for the management of chronic and acute decompensated heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Disease Management; Drug Combinations; Ferric Compounds; Heart Failure; Humans; Ivabradine; Maltose; Tetrazoles; Valsartan | 2016 |
The available intravenous iron formulations: History, efficacy, and toxicology.
Topics: Anemia; Drug Compounding; Ferric Compounds; Ferrosoferric Oxide; Humans; Infusions, Intravenous; Iron; Kidney Failure, Chronic; Maltose; Renal Dialysis | 2017 |
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Global Health; Heart Failure; Hospitalization; Humans; Iron; Iron Deficiencies; Maltose; Survival Rate | 2018 |
Iron deficiency and new insights into therapy.
Topics: Administration, Oral; Anemia, Iron-Deficiency; Australia; Blood Transfusion; Bone Marrow; Child; Female; Ferric Compounds; Humans; Infusions, Intravenous; Iron; Iron Deficiencies; Maltose; Pregnancy | 2017 |
Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Humans; Maltose; Pregnancy; Pregnancy Complications, Hematologic; Quality of Life | 2018 |
[Iron deficiency in ND-CKD: from diagnosis to treatment].
Topics: Anemia, Iron-Deficiency; Biomarkers; Bone Marrow Examination; Erythropoiesis; Ferric Compounds; Ferritins; Gastrointestinal Hemorrhage; Hematinics; Hemoglobins; Hepcidins; Humans; Intestinal Absorption; Iron; Iron Deficiencies; Maltose; Multicenter Studies as Topic; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Reticulocytes; Transferrin | 2017 |
[Iron, a "miralcle cure" for chronic cardiac insufficiency?]
Topics: Aged; Anemia, Iron-Deficiency; Chronic Disease; Comorbidity; Cross-Sectional Studies; Female; Ferric Compounds; Heart Failure; Hemoglobinometry; Humans; Iron Compounds; Male; Maltose; Reference Values; Transferrin | 2018 |
Ferric Carboxymaltose: A Review in Iron Deficiency.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Chronic Disease; Female; Ferric Compounds; Heart Failure; Humans; Inflammatory Bowel Diseases; Kidney Diseases; Maltose; Neoplasms; Postpartum Period; Pregnancy; Treatment Outcome; Uterine Hemorrhage | 2018 |
Iron deficiency in heart failure.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Comorbidity; Ferric Compounds; Heart Failure; Humans; Maltose; Meta-Analysis as Topic; Quality of Life; Randomized Controlled Trials as Topic | 2018 |
Iron Deficiency in Heart Failure: An Overview.
Topics: Administration, Intravenous; Administration, Oral; Anemia, Iron-Deficiency; Cardiovascular Diseases; Comorbidity; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrous Compounds; Heart Failure; Hematinics; Hemoglobins; Hospitalization; Humans; Maltose; Oxygen Consumption; Prevalence; Quality of Life; Stroke Volume; Transferrin; Walk Test | 2019 |
Intravenous iron induced severe hypophophatemia in a gastric bypass patient.
Topics: Female; Ferric Compounds; Gastric Bypass; Humans; Hypophosphatemia; Iron Deficiencies; Maltose; Middle Aged; Obesity, Morbid; Postoperative Complications | 2019 |
A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
Topics: Administration, Intravenous; Administration, Oral; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Hematinics; Hemoglobins; Humans; Maltose | 2019 |
[Heart failure and iron deficiency].
Topics: Aged; Anemia, Iron-Deficiency; Ferric Compounds; Heart Failure; Humans; Iron Deficiencies; Maltose; Quality of Life; Stroke Volume | 2019 |
Efficacy and tolerability of intravenous iron for patients with restless legs syndrome: evidence from randomized trials and observational studies.
Topics: Ferric Compounds; Ferric Oxide, Saccharated; Humans; Injections, Intravenous; Iron-Dextran Complex; Maltose; Observational Studies as Topic; Randomized Controlled Trials as Topic; Restless Legs Syndrome | 2019 |
Iron Infusion and Induced Hypophosphatemia: The Role of Fibroblast Growth Factor-23.
Topics: Anemia, Iron-Deficiency; Drug-Related Side Effects and Adverse Reactions; Ferric Compounds; Fibroblast Growth Factor-23; Hematinics; Humans; Hypophosphatemia; Long Term Adverse Effects; Maltose | 2020 |
FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.
Topics: Anemia, Iron-Deficiency; Bone and Bones; Calcium; Erythropoiesis; Familial Hypophosphatemic Rickets; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypophosphatemia; Inflammation; Iron; Maltose; Phosphates; Protein Processing, Post-Translational; Renal Insufficiency, Chronic; RNA, Messenger; Transcription, Genetic | 2020 |
The Effect of Perioperative Intravenous Iron on Hemoglobin in Surgical Patients: A Meta-Analysis.
Topics: Administration, Intravenous; Administration, Oral; Blood Loss, Surgical; Blood Transfusion; Ferric Compounds; Hemoglobins; Humans; Maltose; Perioperative Care; Postoperative Hemorrhage; Postoperative Period; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
[The beneficial effects of iron supplementation other than improvement of anemia].
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Animals; Ferric Compounds; Ferric Oxide, Saccharated; Heart Failure; Humans; Iron; Maltose; Mice; Randomized Controlled Trials as Topic; Receptors, Transferrin | 2019 |
Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
Topics: Administration, Intravenous; Administration, Oral; Adult; Anemia, Iron-Deficiency; Clinical Trials as Topic; Female; Ferric Compounds; Hematinics; Humans; Inflammatory Bowel Diseases; Male; Maltose; Pyrones; Renal Insufficiency, Chronic; Treatment Outcome | 2021 |
Economic impact of ferric carboxymaltose in haemodialysis patients
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Hematinics; Humans; Iron Deficiencies; Iron Metabolism Disorders; Maltose; Renal Dialysis | 2020 |
Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Fibroblast Growth Factor-23; Humans; Hypophosphatemia; Maltose; Prospective Studies | 2021 |
A Meta-analysis of Intravenous Iron Therapy for Patients With Iron Deficiency and Heart Failure.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Cardiovascular Diseases; Cause of Death; Ferric Compounds; Heart Failure; Hematinics; Hospitalization; Humans; Maltose; Mortality; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome | 2021 |
Parenteral iron therapy and phosphorus homeostasis: A review.
Topics: Anemia, Hypochromic; Calcitriol; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Homeostasis; Humans; Hypophosphatemia; Infusions, Parenteral; Iron; Iron Deficiencies; Kidney; Malabsorption Syndromes; Maltose; Osteomalacia; Parathyroid Hormone; Phosphorus; Phosphorus, Dietary | 2021 |
Interventions for treating iron deficiency anaemia in inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Bias; Colitis, Ulcerative; Crohn Disease; Disaccharides; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Fumarates; Hematinics; Humans; Iron Compounds; Maltose; Middle Aged; Placebos; Pyrones; Randomized Controlled Trials as Topic; Young Adult | 2021 |
Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis.
Topics: Ferric Compounds; Heart Failure; Humans; Iron; Maltose | 2020 |
Indirect comparison between ferric carboxymaltose and oral iron replacement in heart failure with reduced ejection fraction: a network meta-analysis.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Heart Failure; Humans; Iron; Maltose; Network Meta-Analysis | 2021 |
Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Hematinics; Hemoglobins; Humans; Maltose; Pregnancy; Pregnancy Complications, Hematologic; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Recent advances in pharmacological treatment of heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotonic Agents; Drug Combinations; Ferric Compounds; Heart Failure; Heterocyclic Compounds, 2-Ring; Hospitalization; Humans; Iron Deficiencies; Maltose; Pyrimidines; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Urea; Valsartan; Vasodilator Agents; Ventricular Remodeling | 2021 |
[The newest information for iron metabolism: ferric carboxymaltose, a recently available treatment option for iron-deficiency anemia].
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Humans; Iron; Japan; Maltose; Treatment Outcome | 2021 |
Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis.
Topics: Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrous Compounds; Hemoglobins; Humans; Maltose; Nausea; Pregnancy | 2021 |
Safety of Ferric Carboxymaltose in Children: Report of a Case Series from Greece and Review of the Literature.
Topics: Adult; Child; Ferric Compounds; Greece; Humans; Maltose; Prospective Studies | 2022 |
Applying reflective multicriteria decision analysis to understand the value of therapeutic alternatives in the management of gestational and peripartum anaemia in Spain.
Topics: Anemia, Iron-Deficiency; Decision Support Techniques; Female; Ferric Compounds; Ferrous Compounds; Humans; Maltose; Pregnancy; Pregnancy Complications, Hematologic; Risk Assessment; Spain; Stakeholder Participation | 2022 |
A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.
Topics: Anemia, Iron-Deficiency; Cardiovascular Diseases; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Heart Failure; Humans; Incidence; Iron; Maltose; Randomized Controlled Trials as Topic | 2022 |
Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review.
Topics: Administration, Intravenous; Adolescent; Anemia, Iron-Deficiency; Child; Ferric Compounds; Humans; Iron; Iron Deficiencies; Maltose; Prospective Studies; Retrospective Studies; Treatment Outcome | 2022 |
Systematic review and meta-analysis of intravenous iron-carbohydrate complexes in HFrEF patients with iron deficiency.
Topics: Anemia, Iron-Deficiency; Hematinics; Humans; Iron; Iron Deficiencies; Maltose | 2023 |
115 trial(s) available for acebutolol and ferric carboxymaltose
| Article | Year |
|---|---|
Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
Topics: Administration, Oral; Adult; Anemia; Dietary Supplements; Drug Administration Schedule; Female; Ferric Compounds; Ferrous Compounds; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Maltose; Mexico; Postpartum Period; Pregnancy; United States | 2007 |
Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Ferrous Compounds; Hemoglobins; Humans; Infusions, Intravenous; Iron; Iron Deficiencies; Maltose; Postpartum Period; Time Factors; Treatment Outcome | 2008 |
A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Anemia, Iron-Deficiency; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Female; Ferric Compounds; Ferritins; Ferrous Compounds; Germany; Hemoglobinometry; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged | 2008 |
Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial.
Topics: Administration, Oral; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferrous Compounds; Hematinics; Humans; Injections; Maltose; Puerperal Disorders; Treatment Outcome | 2008 |
The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Female; Ferric Compounds; Hematinics; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Premedication; Renal Dialysis; Renal Insufficiency, Chronic | 2009 |
Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Anemia, Iron-Deficiency; Calcium; Female; Ferric Compounds; Ferrous Compounds; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Maltose; Middle Aged; Phosphates; Potassium; Quality of Life; Treatment Outcome; Uterine Hemorrhage | 2009 |
Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.
Topics: Algorithms; Anemia, Iron-Deficiency; Chronic Disease; Clinical Protocols; Double-Blind Method; Female; Ferric Compounds; Heart Failure; Humans; Injections, Intravenous; Male; Maltose; Patient Care; Reference Values; Research Design; Treatment Outcome | 2009 |
Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Topics: Adult; Anemia, Iron-Deficiency; Cross-Over Studies; Double-Blind Method; Female; Ferric Compounds; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Maltose; Middle Aged; Treatment Outcome | 2010 |
Ferric carboxymaltose in patients with heart failure and iron deficiency.
Topics: Aged; Anemia, Iron-Deficiency; Chronic Disease; Female; Ferric Compounds; Ferritins; Follow-Up Studies; Heart Failure; Hematinics; Humans; Iron Deficiencies; Male; Maltose; Quality of Life; Stroke Volume; Ventricular Dysfunction, Left | 2009 |
The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
Topics: Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferritins; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Kidney Diseases; Male; Maltose; Middle Aged; Renal Dialysis; Treatment Outcome; Young Adult | 2010 |
Iron in heart failure: friend or foe?
Topics: Anemia, Iron-Deficiency; Biomarkers; Double-Blind Method; Female; Ferric Compounds; Heart Failure; Hemoglobins; Humans; Iron; Male; Maltose; Treatment Outcome | 2010 |
Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Biomarkers; Cardiovascular Diseases; Chronic Disease; Female; Ferric Compounds; Ferric Oxide, Saccharated; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucaric Acid; Hemoglobins; Humans; Kidney Diseases; Male; Maltose; Middle Aged; Risk Factors; Sucrose; Treatment Outcome | 2010 |
Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Blood Pressure; Body Temperature; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Ferric Compounds; Heart Rate; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged | 2010 |
Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Ferric Compounds; Ferritins; Gastrointestinal Diseases; Hemoglobins; Humans; Male; Maltose; Middle Aged; Patient Selection; Transferrin | 2010 |
A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.
Topics: Administration, Oral; Aged; Anemia, Iron-Deficiency; Female; Ferric Compounds; Glomerular Filtration Rate; Humans; Injections, Intravenous; Iron; Kidney Failure, Chronic; Male; Maltose; Prognosis | 2011 |
FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Comorbidity; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Male; Maltose; Middle Aged; Outcome Assessment, Health Care; Treatment Outcome; Young Adult | 2011 |
Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial.
Topics: Adult; Aged; Brain; Female; Ferric Compounds; Ferritins; Follow-Up Studies; Humans; Iron; Male; Maltose; Middle Aged; Pilot Projects; Placebos; Restless Legs Syndrome; Severity of Illness Index; Treatment Outcome | 2011 |
The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
Topics: Aged; Anemia, Iron-Deficiency; Chronic Disease; Double-Blind Method; Ferric Compounds; Heart Failure; Hematinics; Homeostasis; Humans; Injections, Intravenous; Iron Deficiencies; Maltose; Quality of Life; Treatment Outcome; Ventricular Dysfunction, Left | 2013 |
Ferric carboxymaltose with or without erythropoietin for the prevention of red-cell transfusions in the perioperative period of osteoporotic hip fractures: a randomized contolled trial. The PAHFRAC-01 project.
Topics: Aged; Aged, 80 and over; Anemia; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Erythrocyte Transfusion; Erythropoietin; Female; Ferric Compounds; Hip Fractures; Humans; Male; Maltose; Osteoporotic Fractures; Postoperative Hemorrhage; Research Design; Treatment Outcome | 2012 |
Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Dietary Supplements; Female; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Male; Maltose; Middle Aged; Placebos; Secondary Prevention; Single-Blind Method; Treatment Outcome; Young Adult | 2013 |
Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Female; Ferric Compounds; Follow-Up Studies; Humans; Injections, Intravenous; Iron; Male; Maltose; Middle Aged; Prognosis; Renal Dialysis; Renal Insufficiency, Chronic; Young Adult | 2013 |
Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia.
Topics: Adult; Anemia, Iron-Deficiency; Antimicrobial Cationic Peptides; Biomarkers; Dietary Supplements; Female; Ferric Compounds; Ferritins; Ferrous Compounds; Hemoglobins; Hepcidins; Humans; Injections, Intravenous; Iron, Dietary; Male; Maltose; Predictive Value of Tests; Sensitivity and Specificity; Transferrin | 2013 |
Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations.
Topics: Aged; Anemia, Iron-Deficiency; Biomarkers; Blood Component Removal; Chemistry, Pharmaceutical; Drug Administration Schedule; Dyslipidemias; Female; Ferric Compounds; Ferritins; Germany; Hematinics; Humans; Infusions, Intravenous; Lipoproteins; Male; Maltose; Middle Aged; Time Factors; Transferrin; Treatment Outcome | 2013 |
Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
Topics: Adult; Anemia, Iron-Deficiency; Animals; Calcium; Demography; Erythropoiesis; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Homeostasis; Humans; Iron; Iron-Dextran Complex; Maltose; Mice; Models, Biological; Parathyroid Hormone; Phosphates; Vitamin D | 2013 |
The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
Topics: Aged; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Double-Blind Method; Erythrocyte Indices; Female; Ferric Compounds; Follow-Up Studies; Heart Failure; Hemoglobins; Humans; Injections, Intravenous; Male; Maltose; Prospective Studies; Treatment Outcome | 2013 |
Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Erythropoietin; Female; Ferric Compounds; Hepcidins; Humans; Inflammatory Bowel Diseases; Intercellular Signaling Peptides and Proteins; Male; Maltose; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Count; Prognosis; Prospective Studies; Thrombocytosis; Young Adult | 2013 |
A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Topics: Administration, Oral; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Heart Diseases; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Iron; Male; Maltose; Middle Aged; Risk Factors; Stroke; Treatment Outcome | 2014 |
Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.
Topics: Administration, Intravenous; Aged; Anemia, Iron-Deficiency; Case-Control Studies; Chronic Disease; Deficiency Diseases; Female; Ferric Compounds; Heart Failure; Hematinics; Humans; Iron Deficiencies; Male; Maltose; Middle Aged; Quality of Life; Treatment Outcome | 2013 |
Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
Topics: Aged; Anemia, Iron-Deficiency; Double-Blind Method; Female; Ferric Compounds; Heart Failure; Humans; Internationality; Male; Maltose; Middle Aged; Quality of Life; Retrospective Studies; Treatment Outcome | 2013 |
Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
Topics: Aged; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glomerular Filtration Rate; Glucaric Acid; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Iron; Male; Maltose; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
Topics: Administration, Oral; Adult; Aged; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Ferric Compounds; Ferritins; Ferrous Compounds; Follow-Up Studies; Glomerular Filtration Rate; Hemoglobins; Humans; Injections, Intravenous; Iron; Male; Maltose; Middle Aged; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2014 |
FAIRY: a randomized controlled patient-blind phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) to placebo in patients with acute isovolemic anemia after gastrectomy - study protocol for a randomized contr
Topics: Anemia; Biomarkers; Blood Volume; Clinical Protocols; Female; Ferric Compounds; Gastrectomy; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Male; Maltose; Quality of Life; Republic of Korea; Research Design; Stomach Neoplasms; Time Factors; Treatment Outcome | 2014 |
Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study.
Topics: Adult; Cognition; Dose-Response Relationship, Drug; Endpoint Determination; Erythrocyte Indices; Fatigue; Female; Ferric Compounds; Hemoglobins; Humans; Intention to Treat Analysis; Iron Deficiencies; Maltose; Placebos; Quality of Life; Transferrin | 2014 |
Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Arthroplasty, Replacement, Knee; Female; Ferric Compounds; Ferrous Compounds; Glycine; Humans; Male; Maltose; Middle Aged; Postoperative Complications; Prospective Studies; Single-Blind Method; Spain; Treatment Outcome | 2014 |
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Topics: Administration, Oral; Aged; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferritins; Follow-Up Studies; Hemoglobins; Humans; Injections, Intravenous; Iron; Male; Maltose; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2014 |
The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; C-Reactive Protein; Colorectal Neoplasms; Erythrocyte Transfusion; Erythropoietin; Feasibility Studies; Female; Ferric Compounds; Hemoglobins; Humans; Infusions, Intravenous; Length of Stay; Male; Maltose; Middle Aged; Pilot Projects; Postoperative Complications; Preoperative Care; Transferrins | 2014 |
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Topics: Aged; Cardiotonic Agents; Double-Blind Method; Female; Ferric Compounds; Heart Failure; Hospitalization; Humans; Injections, Intravenous; Iron Deficiencies; Long-Term Care; Male; Maltose; Quality of Life; Treatment Outcome | 2015 |
Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners.
Topics: Adolescent; Adult; Fatigue; Female; Ferric Compounds; Ferritins; Hemoglobins; Humans; Injections, Intravenous; Male; Maltose; Mood Disorders; Psychiatric Status Rating Scales; Running; Treatment Outcome; Young Adult | 2014 |
Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anemia, Iron-Deficiency; Antineoplastic Agents; Female; Ferric Compounds; Hemoglobins; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Maltose; Middle Aged; Multiple Myeloma; Treatment Outcome | 2014 |
The IRONMAN trial: a protocol for a multicentre randomised placebo-controlled trial of intravenous iron in intensive care unit patients with anaemia.
Topics: Anemia; Clinical Protocols; Critical Care; Ferric Compounds; Infusions, Intravenous; Maltose; Research Design | 2014 |
The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
Topics: Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Double-Blind Method; Female; Ferric Compounds; Glomerular Filtration Rate; Heart Failure; Humans; Infusions, Intravenous; Kidney; Male; Maltose; Middle Aged; Renal Insufficiency | 2015 |
Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.
Topics: Administration, Intravenous; Aged; Chronic Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Ferric Compounds; Health Services; Heart Failure; Humans; Inpatients; Iron Deficiencies; Male; Maltose; Middle Aged; Models, Econometric; Outpatients; Quality of Life; Quality-Adjusted Life Years; Sweden | 2015 |
Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Erythropoiesis; Female; Ferric Compounds; Hemoglobins; Humans; Iron; Male; Maltose; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic | 2015 |
PREVENTT: preoperative intravenous iron to treat anaemia in major surgery: study protocol for a randomised controlled trial.
Topics: Abdomen; Administration, Intravenous; Anemia; Biomarkers; Blood Transfusion; Clinical Protocols; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; England; Ferric Compounds; Health Resources; Hematinics; Hemoglobins; Hospital Costs; Humans; Length of Stay; Maltose; Preoperative Care; Recovery of Function; Research Design; Time Factors; Treatment Outcome | 2015 |
Multicentre randomized controlled trial comparing ferric(III)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Clinical Protocols; Colorectal Neoplasms; Dietary Supplements; Female; Ferric Compounds; Ferrous Compounds; Fumarates; Hematinics; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Preoperative Care; Treatment Outcome; Young Adult | 2015 |
The Important Role for Intravenous Iron in Perioperative Patient Blood Management in Major Abdominal Surgery: A Randomized Controlled Trial.
Topics: Abdominal Cavity; Aged; Anemia, Iron-Deficiency; Blood Loss, Surgical; Blood Transfusion; Body Mass Index; Digestive System Surgical Procedures; Female; Ferric Compounds; Follow-Up Studies; Humans; Injections, Intravenous; Length of Stay; Male; Maltose; Middle Aged; Perioperative Care; Postoperative Care; Quality of Life; Treatment Outcome | 2016 |
Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Follow-Up Studies; Glucaric Acid; Hematinics; Hemoglobins; Humans; India; Maltose; Middle Aged; Prospective Studies; Treatment Outcome; Uterine Hemorrhage | 2016 |
Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia.
Topics: Aged; Anemia; Exercise Test; Exercise Tolerance; Female; Ferric Compounds; Follow-Up Studies; Heart Failure; Hematinics; Humans; Longitudinal Studies; Male; Maltose; Middle Aged; Quality of Life; Recovery of Function; Self Report; Treatment Outcome | 2016 |
Ferric carboxymaltose with or without erythropoietin in anemic patients with hip fracture: a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Anemia; Double-Blind Method; Erythrocyte Transfusion; Erythropoietin; Female; Ferric Compounds; Hip Fractures; Humans; Male; Maltose; Quality of Life; Treatment Outcome | 2016 |
Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Hepcidins; Humans; Iron; Male; Maltose; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Time Factors | 2016 |
Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP).
Topics: Administration, Intravenous; Administration, Oral; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferrous Compounds; Humans; Infant, Newborn; Maltose; Pregnancy; Pregnancy Complications, Hematologic; Quality of Life; Treatment Outcome | 2017 |
Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.
Topics: Administration, Intravenous; Aged; Anemia, Iron-Deficiency; Elective Surgical Procedures; Female; Ferric Compounds; Follow-Up Studies; Hemoglobins; Humans; Male; Maltose; Middle Aged; Postoperative Complications; Prognosis; Standard of Care | 2016 |
Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial : A randomized trial of IV iron in critical illness.
Topics: Administration, Intravenous; Adult; Aged; Allografts; Anemia; Confidence Intervals; Critical Illness; Double-Blind Method; Erythrocyte Transfusion; Female; Ferric Compounds; Hemoglobins; Humans; Intensive Care Units; Intention to Treat Analysis; Male; Maltose; Middle Aged | 2016 |
Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Female; Ferric Compounds; Ferric Oxide, Saccharated; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucaric Acid; Hematinics; Humans; Male; Maltose; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
Topics: Adult; Aged; Anemia, Iron-Deficiency; Double-Blind Method; Female; Ferric Compounds; Ferritins; Hemoglobinometry; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Postoperative Complications; Prospective Studies | 2016 |
Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Colorectal Neoplasms; Elective Surgical Procedures; Erythrocyte Transfusion; Female; Ferric Compounds; Ferrous Compounds; Follow-Up Studies; Hematinics; Humans; Injections, Intravenous; Male; Maltose; Middle Aged; Postoperative Complications; Preoperative Care; Prospective Studies; Treatment Outcome | 2017 |
Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Anemia, Iron-Deficiency; Female; Ferric Compounds; Glomerular Filtration Rate; Humans; Iron; Male; Maltose; Prospective Studies; Renal Insufficiency, Chronic; Time Factors | 2017 |
Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.
Topics: Adult; Aged; Anemia; Female; Ferric Compounds; Gastrectomy; Hematinics; Hemoglobins; Humans; Injections; Male; Maltose; Middle Aged; Postoperative Complications; Single-Blind Method | 2017 |
Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.
Topics: Aged; Aged, 80 and over; Female; Ferric Compounds; Ferritins; Hematinics; Humans; Iron Metabolism Disorders; Male; Maltose; Middle Aged; Prospective Studies; Restless Legs Syndrome; Single-Blind Method; Time Factors; Treatment Outcome | 2017 |
A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy.
Topics: Administration, Intravenous; Australia; Biomarkers; Bone and Bones; Case-Control Studies; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Hematinics; Humans; Hypophosphatasia; Male; Maltose; Middle Aged; Phosphates; Pregnancy; Prospective Studies; Renal Insufficiency, Chronic; Treatment Outcome | 2018 |
Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Erythrocyte Indices; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Hematinics; Hemoglobins; Humans; Maltose; Pregnancy; Pregnancy Complications; Treatment Outcome; Young Adult | 2018 |
Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF).
Topics: Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Double-Blind Method; Female; Ferric Compounds; Follow-Up Studies; Heart Failure; Humans; Injections, Intravenous; Iron; Male; Maltose; Middle Aged; Pilot Projects; Prevalence; Retrospective Studies; Singapore; Stroke Volume; Time Factors; Treatment Outcome | 2018 |
Safety and Efficacy of Intravenous Ferric Carboxy Maltose in Iron Deficiency Anaemia During Post-partum Period.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Female; Ferric Compounds; Hematinics; Hemoglobins; Humans; Maltose; Nepal; Postpartum Period; Young Adult | 2018 |
Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.
Topics: Adult; Aged; Anemia, Iron-Deficiency; Drug Hypersensitivity; Female; Ferric Compounds; Ferrosoferric Oxide; Humans; Hypophosphatemia; Male; Maltose; Middle Aged; Treatment Outcome | 2018 |
Efficacy of ferric carboxymaltose (FCM) 500 mg dose for the treatment of Restless Legs Syndrome.
Topics: Administration, Intravenous; Double-Blind Method; Female; Ferric Compounds; Humans; Male; Maltose; Middle Aged; Restless Legs Syndrome; Severity of Illness Index; Treatment Outcome | 2018 |
Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design.
Topics: Aged; Anemia, Iron-Deficiency; Clinical Protocols; Double-Blind Method; Female; Ferric Compounds; Heart Failure; Hematinics; Humans; Infusions, Intravenous; Magnetic Resonance Imaging, Cine; Male; Maltose; Myocardium; Quality of Life; Recovery of Function; Research Design; Severity of Illness Index; Spain; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2018 |
High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.
Topics: Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Ferric Compounds; Heart Failure; Humans; Hypophosphatemia; Infusions, Intravenous; Maltose; Pilot Projects; Prospective Studies; Stroke Volume | 2018 |
Cost-effectiveness analysis of ferric carboxymaltose in pre-operative haemoglobin optimisation in patients undergoing primary knee arthroplasty.
Topics: Anemia, Iron-Deficiency; Arthroplasty, Replacement, Knee; Costs and Cost Analysis; Decision Making; Erythrocyte Transfusion; Female; Ferric Compounds; Humans; Male; Maltose; Preoperative Care | 2018 |
Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
Topics: Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Hemoglobins; Humans; Japan; Maltose; Menorrhagia; Middle Aged; Treatment Outcome; Young Adult | 2019 |
Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Anemia, Iron-Deficiency; Female; Ferric Compounds; Gastrointestinal Diseases; Hemoglobins; Humans; Iron; Male; Maltose; Middle Aged; Prospective Studies | 2018 |
Preoperative Epoetin-α with Intravenous or Oral Iron for Major Orthopedic Surgery: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Drug Therapy, Combination; Epoetin Alfa; Female; Ferric Compounds; Ferrous Compounds; Hematinics; Humans; Iron; Male; Maltose; Middle Aged; Orthopedic Procedures; Postoperative Complications; Preoperative Care; Prospective Studies; Single-Blind Method | 2018 |
Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Ferric Compounds; Ferritins; Gastrointestinal Diseases; Hemoglobins; Japan; Maltose; Treatment Outcome | 2019 |
A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferrous Compounds; Humans; Infusions, Intravenous; Maltose; Middle Aged; Pregnancy; Prospective Studies; Young Adult | 2018 |
Randomized trial of intravenous iron-induced hypophosphatemia.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Calcitriol; Calcium; Female; Ferric Compounds; Ferrosoferric Oxide; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Homeostasis; Humans; Hyperparathyroidism; Hypophosphatemia; Iron; Male; Maltose; Middle Aged; Phosphates; Risk Factors | 2018 |
Single dose of intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of postoperative anaemia in colorectal cancer patients: study protocol for a randomised controlled trial.
Topics: Anemia; Colorectal Neoplasms; Ferric Compounds; Ferric Oxide, Saccharated; Humans; Infusions, Intravenous; Maltose; Postoperative Complications; Randomized Controlled Trials as Topic | 2019 |
Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Erythrocyte Count; Female; Ferric Compounds; Ferric Oxide, Saccharated; Hematinics; Hemoglobins; Humans; India; Iron; Maltose; Pregnancy; Pregnancy Complications; Prenatal Care; Treatment Outcome; Young Adult | 2019 |
Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
Topics: Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Hematinics; Hemoglobins; Humans; Maltose; Menorrhagia; Middle Aged; Outcome Assessment, Health Care; Young Adult | 2019 |
High-dose intravenous versus oral iron in blood donors with iron deficiency: The IronWoMan randomized, controlled clinical trial.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Blood Donors; Female; Ferric Compounds; Ferritins; Ferrous Compounds; Follow-Up Studies; Humans; Male; Maltose; Middle Aged; Prospective Studies; Transferrin; Young Adult | 2020 |
Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Cardiac Surgical Procedures; Double-Blind Method; Drug Therapy, Combination; Erythrocyte Transfusion; Erythropoietin; Female; Ferric Compounds; Folic Acid; Heart Diseases; Humans; Male; Maltose; Middle Aged; Preoperative Care; Prospective Studies; Time Factors; Vitamin B 12 | 2019 |
Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy.
Topics: Aged; Aged, 80 and over; Chronic Disease; Double-Blind Method; Female; Ferric Compounds; Heart Failure; Humans; Iron Deficiencies; Iron Metabolism Disorders; Male; Maltose; Middle Aged; Plasma Volume | 2019 |
Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy.
Topics: Administration, Intravenous; Adult; Cardiac Resynchronization Therapy; Double-Blind Method; Female; Ferric Compounds; Heart Failure; Humans; Iron Deficiencies; Male; Maltose; Prospective Studies; Ventricular Remodeling | 2019 |
Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
Topics: Aged; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Double-Blind Method; Female; Ferric Compounds; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Injections, Intravenous; Inpatients; Male; Maltose; Middle Aged; Quality of Life; Retrospective Studies; Survival Rate; Switzerland; Treatment Outcome | 2019 |
Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-deficiency Anemia.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Asian People; Female; Ferric Compounds; Ferritins; Humans; Iron; Male; Maltose | 2020 |
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
Topics: Adult; Anemia, Iron-Deficiency; Biomarkers; Disaccharides; Female; Ferric Compounds; Headache; Hematinics; Humans; Hypophosphatemia; Incidence; Male; Maltose; Middle Aged; Nausea; Phosphates | 2020 |
Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial.
Topics: Administration, Intravenous; Aged; Anemia, Iron-Deficiency; Double-Blind Method; Female; Ferric Compounds; Heart Failure; Hematinics; Humans; Iron; Magnetic Resonance Imaging; Male; Maltose; Middle Aged; Myocardium | 2020 |
On the relevance of preoperative haemoglobin optimisation within a Patient Blood Management programme for elective hip arthroplasty surgery.
Topics: Aged; Aged, 80 and over; Anemia; Arthroplasty, Replacement, Hip; Elective Surgical Procedures; Erythrocyte Transfusion; Female; Ferric Compounds; Hemoglobins; Humans; Length of Stay; Male; Maltose; Middle Aged; Retrospective Studies | 2020 |
The Effect of Parenteral or Oral Iron Supplementation on Fatigue, Sleep, Quality of Life and Restless Legs Syndrome in Iron-Deficient Blood Donors: A Secondary Analysis of the IronWoMan RCT.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Blood Donors; Dietary Supplements; Fatigue Syndrome, Chronic; Female; Ferric Compounds; Humans; Infusions, Intravenous; Iron, Dietary; Male; Maltose; Middle Aged; Quality of Life; Restless Legs Syndrome; Severity of Illness Index; Sleep Wake Disorders; Treatment Outcome; Young Adult | 2020 |
A randomized controlled trial comparing oral and intravenous iron supplementation after Roux-en-Y gastric bypass surgery.
Topics: Administration, Intravenous; Administration, Oral; Adult; Dietary Supplements; Female; Ferric Compounds; Ferritins; Ferrous Compounds; Gastric Bypass; Humans; Iron Compounds; Iron Deficiencies; Maltose; Postoperative Complications; Treatment Outcome | 2020 |
Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea.
Topics: Anemia; Antineoplastic Agents; Biomarkers; Erythropoietin; Female; Ferric Compounds; Hemoglobins; Hepcidins; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Neoplasms; Pilot Projects; Republic of Korea; Transferrin; Treatment Outcome | 2020 |
Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial.
Topics: Administration, Intravenous; Aged; Double-Blind Method; Dyspnea; Exercise Tolerance; Female; Ferric Compounds; Hemoglobins; Humans; Iron Deficiencies; Male; Maltose; Middle Aged; Oxygen; Pulmonary Disease, Chronic Obstructive; Quality of Life; Walk Test | 2020 |
Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
Topics: Adult; Anemia, Iron-Deficiency; Double-Blind Method; Female; Ferric Compounds; Fibroblast Growth Factor-23; Humans; Hypophosphatemia; Iron; Male; Maltose; Prospective Studies | 2020 |
The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial.
Topics: Administration, Intravenous; Adult; Fatigue; Female; Ferric Compounds; Humans; Iron Deficiencies; Male; Maltose; Middle Aged; Treatment Outcome | 2020 |
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Double-Blind Method; Female; Ferric Compounds; Heart Failure; Hospitalization; Humans; Male; Maltose; Middle Aged; Patient Discharge; Treatment Outcome; Ventricular Function, Left | 2020 |
Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferrous Compounds; Folic Acid; Hemoglobins; Humans; Iron; Maltose; Postnatal Care; Postpartum Period; Pregnancy; Tanzania; Treatment Outcome; Young Adult | 2021 |
Safety of rapid injection of undiluted ferric carboxymaltose to patients with iron-deficiency anaemia: a Phase II single-arm study.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Humans; Iron; Maltose | 2021 |
Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Anemia, Iron-Deficiency; Colitis, Ulcerative; Comparative Effectiveness Research; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Hematinics; Hemoglobins; Humans; Iron; Male; Maltose; Middle Aged; Prospective Studies; Treatment Outcome | 2021 |
Intravenous iron supplementation after liver surgery: Impact on anemia, iron, and hepcidin levels-a randomized controlled trial.
Topics: Aged; Anemia; C-Reactive Protein; Ferric Compounds; Ferritins; Hepatectomy; Hepcidins; Humans; Infusions, Intravenous; Interleukin-6; Iron; Male; Maltose; Postoperative Care; Postoperative Complications | 2021 |
Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Hemoglobins; Humans; Inflammatory Bowel Diseases; Male; Maltose; Pyrones; Treatment Outcome | 2022 |
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Heart Failure; Humans; Iron; Maltose; Quality of Life; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2021 |
Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia.
Topics: Anemia, Iron-Deficiency; Double-Blind Method; Ferric Compounds; Humans; Maltose; Restless Legs Syndrome; Treatment Outcome | 2021 |
The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.
Topics: Cardiac Resynchronization Therapy; Ferric Compounds; Heart Failure; Humans; Iron Deficiencies; Maltose; Stroke Volume; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Rationale and design of the IRON-AF study: a double-blind, randomised, placebo-controlled study to assess the effect of intravenous ferric carboxymaltose in patients with atrial fibrillation and iron deficiency.
Topics: Anemia, Iron-Deficiency; Atrial Fibrillation; Australia; Double-Blind Method; Ferric Compounds; Humans; Iron; Maltose | 2021 |
Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
Topics: Adult; Aged; Anemia, Iron-Deficiency; Austria; Biomarkers; Drug Administration Schedule; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Transferrin; Treatment Outcome | 2021 |
Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Double-Blind Method; Female; Ferric Compounds; Humans; Induction Chemotherapy; Male; Maltose; Middle Aged; Neoplasms; Placebo Effect; Treatment Outcome | 2021 |
Single-dose intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of post-operative anaemia in colorectal cancer patients: a randomised controlled trial.
Topics: Administration, Intravenous; Anemia; Anemia, Iron-Deficiency; Colorectal Neoplasms; Ferric Compounds; Ferric Oxide, Saccharated; Hemoglobins; Humans; Iron; Maltose | 2022 |
Protocol for a multicentre, parallel-group, open-label randomised controlled trial comparing ferric carboxymaltose with the standard of care in anaemic Malawian pregnant women: the REVAMP trial.
Topics: Anemia; Anemia, Iron-Deficiency; Australia; Female; Ferric Compounds; Humans; Malawi; Maltose; Multicenter Studies as Topic; Pregnancy; Pregnant Women; Randomized Controlled Trials as Topic; Standard of Care | 2021 |
Intravenous iron to treat anaemia following critical care: a multicentre feasibility randomised trial.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Critical Care; Feasibility Studies; Female; Ferric Compounds; Follow-Up Studies; Hematinics; Hemoglobins; Humans; Length of Stay; Male; Maltose; Middle Aged; Patient Readmission; Patient Reported Outcome Measures; Young Adult | 2022 |
Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial-IRON Trial.
Topics: Aged; Ferric Compounds; Heart Failure; Humans; Magnetic Resonance Imaging, Cine; Magnetic Resonance Spectroscopy; Male; Maltose; Stroke Volume; Ventricular Function, Left | 2022 |
The effect of intravenous ferric carboxymaltose on right ventricular function - insights from the IRON-CRT trial.
Topics: Cardiac Resynchronization Therapy; Ferric Compounds; Heart Failure; Humans; Maltose; Stroke Volume; Ventricular Dysfunction, Right; Ventricular Function, Left; Ventricular Function, Right | 2022 |
Intravenous Iron Replacement Improves Exercise Tolerance in COPD: A Single-Blind Randomized Trial.
Topics: Anemia, Iron-Deficiency; Exercise Tolerance; Ferric Compounds; Ferritins; Humans; Iron; Iron Deficiencies; Maltose; Pulmonary Disease, Chronic Obstructive; Quality of Life; Single-Blind Method; Transferrins; Treatment Outcome | 2022 |
Testing equivalence of two doses of intravenous iron to treat iron deficiency in pregnancy: A randomised controlled trial.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Iron; Iron Deficiencies; Maltose; Pregnancy | 2023 |
Perioperative management with ferric carboxymaltose and tranexamic acid to reduce transfusion rate in gynaecological carcinoma surgery (TRANAFER-Study): study protocol for a single-blind, monocentre, randomised trial.
Topics: Anemia; Blood Transfusion; Carcinoma; Female; Ferric Compounds; Gynecologic Surgical Procedures; Humans; Iron; Maltose; Randomized Controlled Trials as Topic; Single-Blind Method; Tranexamic Acid | 2022 |
Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammatory Bowel Disease: The POPEYE Randomized Controlled Clinical Trial.
Topics: Administration, Oral; Anemia; Anemia, Iron-Deficiency; Child; Ferric Compounds; Hemoglobins; Humans; Inflammatory Bowel Diseases; Iron; Maltose; Treatment Outcome | 2023 |
Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
Topics: Anemia; Female; Ferric Compounds; Ferritins; Heart Failure; Hemoglobins; Humans; Iron; Iron Deficiencies; Male; Maltose; Quality of Life; Transferrins; Treatment Outcome | 2023 |
Intravenous iron administration before cardiac surgery reduces red blood cell transfusion in patients without anaemia.
Topics: Administration, Intravenous; Anemia; Cardiac Surgical Procedures; Double-Blind Method; Erythrocyte Transfusion; Ferric Compounds; Hemoglobins; Humans; Iron; Maltose | 2023 |
244 other study(ies) available for acebutolol and ferric carboxymaltose
| Article | Year |
|---|---|
Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
Topics: Anemia; Drug Approval; Female; Ferric Compounds; Heart Diseases; Hematinics; Humans; Infusions, Intravenous; Maltose; Puerperal Disorders; Randomized Controlled Trials as Topic; United States | 2008 |
Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients.
Topics: Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Kidney Transplantation; Male; Maltose; Prospective Studies; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome | 2009 |
Anemia and iron deficiency--new therapeutic targets in heart failure?
Topics: Anemia, Iron-Deficiency; Chronic Disease; Ferric Compounds; Heart Failure; Hematinics; Humans; Iron Deficiencies; Maltose; Stroke Volume | 2009 |
Progress in intravenous iron treatment.
Topics: Administration, Oral; Anemia, Iron-Deficiency; Erythropoietin; Ferric Compounds; Humans; Injections, Intramuscular; Injections, Intravenous; Iron; Iron Overload; Maltose; Recombinant Proteins; Renal Dialysis | 2010 |
In vitro studies of ferric carboxymaltose on placental permeability using the dual perfusion model of human placenta.
Topics: Arteries; Female; Ferric Compounds; Humans; Iron; Iron Radioisotopes; Maltose; Perfusion; Permeability; Placenta; Pregnancy; Transferrin; Veins | 2010 |
Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Topics: Anemia; Anemia, Iron-Deficiency; Breast Feeding; Female; Ferric Compounds; Ferritins; Heart Failure; Humans; Infant; Inflammatory Bowel Diseases; Maltose; Pilot Projects; Puerperal Disorders; Randomized Controlled Trials as Topic; Renal Insufficiency; Safety; Transferrin | 2010 |
Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient.
Topics: Adult; Female; Ferric Compounds; Glomerular Filtration Rate; Humans; Hypophosphatemia; Injections, Intravenous; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Maltose; Phosphates; Polycystic Kidney Diseases; Reference Values; Transplantation, Homologous | 2010 |
The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Drug Costs; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Health Care Costs; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Male; Maltose; Middle Aged; Young Adult | 2010 |
Clinical perspective: iron replacement therapy in chronic heart failure.
Topics: Anemia, Iron-Deficiency; Chronic Disease; Ferric Compounds; Heart Failure; Hematinics; Humans; Infusions, Intravenous; Iron-Dextran Complex; Maltose | 2011 |
IBD: Intravenous iron in IBD--what's the best preparation?
Topics: Anemia, Iron-Deficiency; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Inflammatory Bowel Diseases; Injections, Intravenous; Maltose; Quality of Life; Treatment Outcome | 2011 |
A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Costs and Cost Analysis; Elective Surgical Procedures; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Injections, Intravenous; Male; Maltose; Middle Aged; Preoperative Care | 2011 |
Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.
Topics: Animals; Antioxidants; Blood Pressure; Creatinine; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Heart; Hematinics; Immunohistochemistry; Inflammation; Injections, Intravenous; Iron-Dextran Complex; Kidney; Lipid Peroxidation; Liver; Magnetite Nanoparticles; Male; Maltose; Molecular Weight; Oxidative Stress; Proteinuria; Rats; Rats, Sprague-Dawley | 2011 |
Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective.
Topics: Anemia; Blood Transfusion; Cost Savings; Costs and Cost Analysis; Dose-Response Relationship, Drug; Erythropoiesis; Female; Ferric Compounds; France; Hematinics; Humans; Maltose; Models, Economic | 2012 |
Anaemia tolerance: bridging with intravenous ferric carboxymaltose in a patient with acute post-haemorrhagic anaemia.
Topics: Accidents, Traffic; Adolescent; Anemia; Erythrocyte Count; Ferric Compounds; Hemoglobins; Hemorrhage; Humans; Male; Maltose; Wounds and Injuries | 2012 |
Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Cohort Studies; Female; Ferric Compounds; Ferritins; Hemoglobins; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Iron; Male; Maltose; Middle Aged; Treatment Outcome; Young Adult | 2012 |
Intravenous ferric carboxymaltose accelerates erythropoietic recovery from experimental malarial anemia.
Topics: Anemia, Iron-Deficiency; Animals; Disease Models, Animal; Erythropoiesis; Ferric Compounds; Growth Substances; Malaria; Male; Maltose; Mice; Mice, Inbred A; Plasmodium chabaudi; Treatment Outcome | 2012 |
Investigating the response to intravenous iron in restless legs syndrome: an observational study.
Topics: Adult; Aged; Comorbidity; Female; Ferric Compounds; Ferritins; Humans; Injections, Intravenous; Iron; Iron Deficiencies; Male; Maltose; Middle Aged; Prospective Studies; Restless Legs Syndrome; Severity of Illness Index; Treatment Outcome | 2012 |
Efficacy and toxicity of intravenous iron in a mouse model of critical care anemia*.
Topics: Anemia; Animals; Antimicrobial Cationic Peptides; Catalase; Diet; Disease Models, Animal; Ferric Compounds; Hematinics; Hemoglobins; Hepcidins; Inflammation; Injections, Intravenous; Iron; Liver; Luminescence; Maltose; Mice; Mice, Inbred C57BL; Phlebotomy; Random Allocation; Reactive Oxygen Species; RNA, Messenger; Sepsis; Spleen; Superoxide Dismutase; Trace Elements; Zymosan | 2012 |
Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK.
Topics: Aged; Cost-Benefit Analysis; Female; Ferric Compounds; Health Care Costs; Heart Failure; Humans; Infusions, Intravenous; Iron Deficiencies; Male; Maltose; Models, Economic; Probability; Quality-Adjusted Life Years; Surveys and Questionnaires; United Kingdom | 2012 |
Resurrecting the iron age*.
Topics: Anemia; Animals; Ferric Compounds; Hematinics; Maltose | 2012 |
Intravenous iron among cystic fibrosis patients.
Topics: Anemia, Iron-Deficiency; Cystic Fibrosis; Ferric Compounds; Humans; Hypersensitivity; Infusions, Intravenous; Iron; Lung Diseases; Maltose; Retrospective Studies | 2012 |
Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Blood Transfusion; Cohort Studies; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Injections, Intravenous; Maltose; Puerperal Disorders; Retrospective Studies; Treatment Outcome | 2012 |
Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
Topics: Administration, Intravenous; Adolescent; Adult; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Maltose; Middle Aged; Pregnancy; Pregnancy Complications, Hematologic; Retrospective Studies; Young Adult | 2012 |
An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
Topics: Administration, Intravenous; Ambulatory Care Facilities; Anemia, Iron-Deficiency; Clinical Protocols; Costs and Cost Analysis; Decision Support Techniques; Efficiency, Organizational; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hospitalization; Humans; Maltose; Patient Preference; Renal Insufficiency, Chronic; Transportation; United Kingdom | 2013 |
Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency.
Topics: Ambulatory Care; Anemia, Iron-Deficiency; Costs and Cost Analysis; Ferric Compounds; Humans; Infusions, Intravenous; Maltose; Monte Carlo Method; Retrospective Studies; Sucrose | 2012 |
Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia.
Topics: Aged; Anemia, Iron-Deficiency; Antineoplastic Agents; Female; Ferric Compounds; Ferritins; Hematinics; Hemoglobins; Humans; Male; Maltose; Middle Aged; Neoplasms; Treatment Outcome | 2013 |
Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients.
Topics: Adult; Anemia, Iron-Deficiency; Bariatric Surgery; Biomarkers; Dietary Supplements; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferritins; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Iron, Dietary; Malabsorption Syndromes; Male; Maltose; Middle Aged; Obesity, Morbid; Parenteral Nutrition; Postoperative Complications; Randomized Controlled Trials as Topic; Retrospective Studies; Transferrin; Treatment Outcome; United States | 2013 |
Acute and sub-acute effect of ferric carboxymaltose on inflammation and adhesion molecules in patients with predialysis chronic renal failure.
Topics: Aged; Anemia, Iron-Deficiency; Cell Adhesion Molecules; Female; Ferric Compounds; Humans; Inflammation; Kidney Failure, Chronic; Male; Maltose; Prospective Studies | 2013 |
Oxidative effect of several intravenous iron complexes in the rat.
Topics: Administration, Intravenous; Animals; Dinitrobenzenes; Dose-Response Relationship, Drug; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Iron-Dextran Complex; Maltose; Oxidative Stress; Rats; Tissue Distribution; Tyrosine | 2013 |
Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey.
Topics: Anemia, Iron-Deficiency; Central Venous Catheters; Ferric Compounds; Ferric Oxide, Saccharated; France; Glucaric Acid; Humans; Infusions, Intravenous; Maltose; Neoplasms; Practice Patterns, Physicians'; Surveys and Questionnaires | 2013 |
Monitoring iron therapy in chronic heart failure.
Topics: Anemia, Iron-Deficiency; Erythrocyte Indices; Female; Ferric Compounds; Heart Failure; Hemoglobins; Humans; Male; Maltose | 2013 |
Intravenous iron supplementation in distance runners with low or suboptimal ferritin.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Anaerobic Threshold; Dietary Supplements; Female; Ferric Compounds; Ferritins; Hematinics; Hemoglobins; Humans; Male; Maltose; Oxygen Consumption; Physical Endurance; Running; Time Factors; Young Adult | 2014 |
Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Colitis, Ulcerative; Crohn Disease; Erythrocyte Indices; Female; Ferric Compounds; Ferritins; Guideline Adherence; Hematinics; Hemoglobins; Humans; Iron Deficiencies; Male; Maltose; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Quality of Life; Sweden; Transferrin; Young Adult | 2013 |
Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Male; Maltose; Middle Aged; Phosphates; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2013 |
[Iron substitution in outpatients in Switzerland: Increase of costs associated with intravenous administration].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia, Iron-Deficiency; Child; Child, Preschool; Cost Savings; Cross-Sectional Studies; Drug Costs; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hemoglobinometry; Humans; Infant; Infusions, Intravenous; Iron Compounds; Male; Maltose; Middle Aged; National Health Programs; Off-Label Use; Retrospective Studies; Switzerland; Young Adult | 2013 |
Ferric carboxymaltose approved for iron deficiency anemia.
Topics: Anemia, Iron-Deficiency; Drug Approval; Ferric Compounds; Humans; Infusions, Intravenous; Maltose | 2013 |
Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data.
Topics: Anemia, Iron-Deficiency; Budgets; Cost Savings; Drug Substitution; Female; Ferric Compounds; Ferric Oxide, Saccharated; Financing, Personal; Glucaric Acid; Humans; Maltose; National Health Programs; Switzerland | 2014 |
Ferric carboxymaltose (Injectafer) for iron deficiency anemia.
Topics: Adult; Anemia, Iron-Deficiency; Drug Approval; Ferric Compounds; Humans; Infusions, Intravenous; Maltose; United States; United States Food and Drug Administration | 2013 |
[Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron].
Topics: Aged; Anemia, Iron-Deficiency; Causality; Diabetes Mellitus, Type 2; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hepatitis C, Chronic; Humans; Hypocalcemia; Hypophosphatemia; Infusions, Intravenous; Male; Maltose | 2014 |
Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient.
Topics: Administration, Oral; Anemia, Iron-Deficiency; Anorexia; Bulimia; Dietary Supplements; Female; Ferric Compounds; Humans; Hypophosphatemia; Injections, Intravenous; Malnutrition; Maltose; Parenteral Nutrition; Phosphates; Weight Loss; Young Adult | 2014 |
Intravenous ferric carboxymaltose for anaemia in pregnancy.
Topics: Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Follow-Up Studies; Gestational Age; Hemoglobins; Humans; Infant, Newborn; Infusions, Intravenous; Iron; Maltose; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Prospective Studies; Treatment Outcome | 2014 |
Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Biomarkers; Drug Administration Schedule; Erythrocytes; Erythropoiesis; Female; Ferric Compounds; Glutathione Peroxidase; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Male; Maltose; Middle Aged; Multivariate Analysis; Odds Ratio; Oxidative Stress; Predictive Value of Tests; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2014 |
[Iron deficiency anemia and anemia of chronic disease (ACD)].
Topics: Adult; Anemia, Iron-Deficiency; Chronic Disease; Diagnosis, Differential; Erythrocyte Indices; Female; Ferric Compounds; Ferritins; Hemoglobinometry; Humans; Infusions, Intravenous; Iron Deficiencies; Maltose; Menorrhagia; Transferrin | 2014 |
Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study.
Topics: Aged; Anemia, Iron-Deficiency; Exercise Test; Female; Ferric Compounds; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Maltose; Middle Aged; Pilot Projects; Prospective Studies; Quality of Life | 2014 |
Ferric carboxymaltose increases epoetin-α response and prevents iron deficiency before elective orthopaedic surgery.
Topics: Aged; Drug Synergism; Elective Surgical Procedures; Epoetin Alfa; Erythropoietin; Female; Ferric Compounds; Hematinics; Hemoglobins; Humans; Iron; Iron Deficiencies; Male; Maltose; Middle Aged; Orthopedic Procedures; Preoperative Care; Recombinant Proteins | 2014 |
Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
Topics: Administration, Intravenous; Animals; Apoptosis; Caspase 3; Disaccharides; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Iron-Dextran Complex; Kidney; Liver; Male; Maltose; Models, Animal; Myocardium; Rats; Tyrosine | 2015 |
Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases.
Topics: Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Female; Ferric Compounds; Gastrointestinal Diseases; Humans; Infant; Infant, Newborn; Inflammatory Bowel Diseases; Infusions, Intravenous; Male; Maltose; Retrospective Studies; Treatment Outcome | 2014 |
Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity.
Topics: Ascorbic Acid; Cell Line; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hep G2 Cells; Humans; Iron; Liver; Macrophages; Maltose | 2015 |
[Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studies].
Topics: Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Chronic Disease; Dose-Response Relationship, Drug; Female; Ferric Compounds; Follow-Up Studies; Germany; Hemoglobinometry; Humans; Infusions, Intravenous; Male; Maltose; Transferrin | 2014 |
[What is essential in diagnosis?].
Topics: Anemia, Iron-Deficiency; Bone Marrow Examination; Diagnosis, Differential; Early Diagnosis; Ferric Compounds; Ferritins; Hemoglobinometry; Humans; Maltose; Predictive Value of Tests | 2014 |
Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia.
Topics: Administration, Intravenous; Administration, Oral; Anemia, Iron-Deficiency; Biomarkers; C-Reactive Protein; Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Crohn Disease; Ferric Compounds; Ferrous Compounds; Hematinics; Hemoglobins; Humans; Inflammation Mediators; Interleukin-6; Maltose; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Treatment Outcome | 2015 |
[Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect].
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Female; Ferric Compounds; Hematinics; Humans; Hypophosphatemia; Infusions, Intravenous; Logistic Models; Male; Maltose; Middle Aged; Retrospective Studies; Treatment Outcome | 2015 |
A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain.
Topics: Aged; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Drug Costs; Female; Ferric Compounds; Follow-Up Studies; Heart Failure; Humans; Incidence; Male; Maltose; Spain | 2015 |
Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Benzamides; Cell Proliferation; Deficiency Diseases; Dichloroacetic Acid; Disease Models, Animal; Erythropoiesis; Ferric Compounds; Ferritins; Glycolysis; Hematinics; Homeostasis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Imatinib Mesylate; Iron; Iron Deficiencies; Liver; Male; Maltose; Piperazines; Pulmonary Artery; Pyrimidines; Rats, Sprague-Dawley; Signal Transduction; Time Factors; Transferrin; Vascular Remodeling | 2015 |
Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
Topics: Chemistry, Physical; Disaccharides; Ferric Compounds; Ferrosoferric Oxide; Iron Compounds; Maltose; X-Ray Diffraction | 2015 |
Spontaneous bacterial peritonitis in a patient with anorexia nervosa with profound zinc and iron deficiency.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anemia, Iron-Deficiency; Anorexia Nervosa; Escherichia coli Infections; Female; Ferric Compounds; Humans; Maltose; Peritonitis; Zinc | 2015 |
Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Antineoplastic Agents; Female; Ferric Compounds; France; Hematinics; Hematologic Neoplasms; Hemoglobins; Humans; Iron; Male; Maltose; Middle Aged; Prospective Studies; Young Adult | 2016 |
TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Topics: Aged; Anemia, Iron-Deficiency; Biomarkers; Blood Component Removal; Drug Administration Schedule; Female; Ferric Compounds; Ferritins; Germany; Hematinics; Humans; Hyperlipoproteinemias; Infusions, Intravenous; Iron; Lipoproteins, LDL; Male; Maltose; Middle Aged; Prospective Studies; Time Factors; Transferrin; Treatment Outcome | 2015 |
Drugs for urologic disorders.
Topics: Acetanilides; Azasteroids; Drug Combinations; Dutasteride; Ferric Compounds; Gels; Humans; Injections; Maltose; Mandelic Acids; Sulfonamides; Tamsulosin; Thiazoles; Urologic Diseases; Urological Agents | 2015 |
Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations.
Topics: Animals; Cation Transport Proteins; Cell Line; Cell Survival; Disaccharides; Epithelial Cells; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrosoferric Oxide; Glucaric Acid; Hepcidins; Humans; Iron; Iron-Dextran Complex; Kidney; Lipid Peroxidation; Macrophages, Peritoneal; Maltose; Oxidative Stress; Primary Cell Culture; Rats; Tumor Necrosis Factor-alpha | 2015 |
Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
Topics: Adult; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Drug Administration Schedule; Ferric Compounds; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Infusions, Intravenous; Male; Maltose; Middle Aged; Patient Compliance; Pilot Projects; Prospective Studies; Treatment Outcome | 2015 |
Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.
Topics: Aged; Anemia, Iron-Deficiency; Female; Ferric Compounds; Follow-Up Studies; Heart Failure; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Prognosis; Treatment Outcome; Ventricular Dysfunction, Left | 2016 |
Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Cohort Studies; Colonic Neoplasms; Costs and Cost Analysis; Female; Ferric Compounds; Humans; Iron; Male; Maltose; Middle Aged; Monte Carlo Method; Preoperative Care; Retrospective Studies; Sucrose | 2016 |
Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Double-Blind Method; Female; Ferric Compounds; Ferritins; Humans; Maltose; Pilot Projects; Pregnancy; Pregnancy Complications; Prospective Studies; Restless Legs Syndrome; Switzerland; Time Factors; Treatment Outcome | 2015 |
Severe Acute Anemia After Liver Transplantation in an Elderly Jehovah's Witness Treated With High-dose Erythropoietin and Ferric Carboxymaltose: A Case Report.
Topics: Anemia; Blood Transfusion; Erythropoietin; Female; Ferric Compounds; Humans; Jehovah's Witnesses; Liver Transplantation; Maltose; Middle Aged; Reticulocyte Count; Shock, Hemorrhagic; Treatment Outcome; Treatment Refusal | 2015 |
A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia.
Topics: Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Ferric Compounds; Humans; Infusions, Intravenous; Maltose; Middle Aged; Treatment Outcome | 2016 |
Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia.
Topics: Aged; Anemia; Blood Transfusion; Colonic Neoplasms; Erythrocyte Indices; Female; Ferric Compounds; Hemoglobins; Humans; Iron; Length of Stay; Male; Maltose; Postoperative Complications; Transplantation, Homologous; Treatment Outcome | 2016 |
Implementing a blood management protocol during the entire perioperative period allows a reduction in transfusion rate in major orthopedic surgery: a before-after study.
Topics: Adult; Anemia; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Transfusion; Controlled Before-After Studies; Erythropoietin; Female; Ferric Compounds; Humans; Male; Maltose; Orthopedic Procedures; Perioperative Period; Postoperative Period; Prospective Studies; Tranexamic Acid | 2016 |
TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
Topics: Adult; Aged; Anemia, Iron-Deficiency; Crohn Disease; Female; Ferric Compounds; Humans; Male; Maltose; Middle Aged; Prospective Studies; Quality of Life; Severity of Illness Index; Treatment Outcome; Young Adult | 2015 |
Ferrous iron content of intravenous iron formulations.
Topics: Administration, Intravenous; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Ferrous Compounds; Glucaric Acid; Iron-Dextran Complex; Maltose | 2016 |
Impact of a blood management protocol on transfusion rates and outcomes following total hip and knee arthroplasty.
Topics: Anemia; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Transfusion; Clinical Protocols; Epoetin Alfa; Ferric Compounds; Ferritins; Hematinics; Hemoglobins; Hospitals, General; Humans; Length of Stay; Maltose; Patient Readmission; Postoperative Complications; Preoperative Care; Retrospective Studies; United Kingdom | 2016 |
High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Male; Maltose; Middle Aged; Prospective Studies; Quality of Life; Young Adult | 2016 |
Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.
Topics: Anemia, Iron-Deficiency; Case-Control Studies; Cell Differentiation; Dendritic Cells; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Injections, Intravenous; Iron Compounds; Macrophages; Maltose; MicroRNAs; Monocytes; Phagocytosis | 2016 |
[Iron deficiency therapy: focus is on the patient].
Topics: Anemia, Iron-Deficiency; Ferric Compounds; General Practice; Humans; Infusions, Intravenous; Maltose; Prospective Studies; Quality of Life | 2016 |
Introduction.
Topics: Antibodies, Monoclonal, Humanized; Ferric Compounds; Health Facilities; Humans; Inflammatory Bowel Diseases; Infliximab; Infusions, Intravenous; Maltose; Patient Compliance; Patient Education as Topic | 2016 |
Iron and vitamin D deficiency in inflammatory bowel disease.
Topics: Administration, Oral; Anemia, Iron-Deficiency; Cholecalciferol; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Injections, Intramuscular; Maltose; Vitamin D Deficiency | 2016 |
Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymaltose.
Topics: Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Dialysis; Drug Monitoring; Erythropoiesis; Female; Ferric Compounds; Hepcidins; Humans; Male; Maltose; Middle Aged; Prognosis; Prospective Studies; Receptors, Transferrin; Renal Insufficiency, Chronic; Sensitivity and Specificity | 2016 |
Intravenous Iron Carboxymaltose as a Potential Therapeutic in Anemia of Inflammation.
Topics: Administration, Intravenous; Anemia; Animals; Biomarkers; Brucella abortus; Cytokines; Diet; Ferric Compounds; Hepcidins; Inflammation; Iron; Maltose; Mice; Reticulocytes; RNA, Messenger | 2016 |
Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure.
Topics: Animals; Cardiotonic Agents; Dopamine; Ferric Compounds; Ferritins; Heart Failure; Humans; Iron; Iron Deficiencies; Iron-Regulatory Proteins; Magnetic Resonance Angiography; Maltose; Mitochondria, Heart; Myocytes, Cardiac; Phenotype; RNA, Messenger; Ventricular Function, Left | 2017 |
Postoperative intravenous iron: a simple strategy to improve outcomes.
Topics: Anemia; Ferric Compounds; Humans; Iron; Maltose; Prospective Studies | 2016 |
Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
Topics: Administration, Intravenous; Adolescent; Anemia, Iron-Deficiency; Child; Crohn Disease; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Follow-Up Studies; Glucaric Acid; Hemoglobins; Humans; Male; Maltose; Portugal; Prospective Studies; Transferrin | 2017 |
Ferric carboxymaltose reduces the number of red blood cell units transfused and allows transfusion independence to be obtained in patients with iron deficiency anemia secondary to gastrointestinal chronic blood loss.
Topics: Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Blood Transfusion; Female; Ferric Compounds; Gastrointestinal Hemorrhage; Humans; Male; Maltose; Middle Aged; Retrospective Studies | 2016 |
Usefulness of Iron Deficiency Correction in Management of Patients With Heart Failure [from the Registry Analysis of Iron Deficiency-Heart Failure (RAID-HF) Registry].
Topics: Aged; Aged, 80 and over; Anemia, Iron-Deficiency; C-Reactive Protein; Cohort Studies; Disease Management; Female; Ferric Compounds; Germany; Heart Failure; Humans; Iron; Logistic Models; Male; Maltose; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Odds Ratio; Peptide Fragments; Prevalence; Registries; Switzerland; Trace Elements; Treatment Outcome | 2016 |
Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron.
Topics: Administration, Oral; Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Cohort Studies; Female; Ferric Compounds; Humans; Infant; Infusions, Intravenous; Iron; Male; Maltose; Retrospective Studies; Treatment Outcome | 2017 |
High-dose intravenously administered iron versus orally administered iron in blood donors with iron deficiency: study protocol for a randomised, controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Biomarkers; Blood Donors; Clinical Protocols; Deficiency Diseases; Erythrocyte Count; Female; Ferric Compounds; Ferrous Compounds; Hematinics; Humans; Infusions, Intravenous; Iron; Iron Deficiencies; Male; Maltose; Middle Aged; Prospective Studies; Research Design; Time Factors; Transferrin; Treatment Outcome; Young Adult | 2016 |
Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome.
Topics: Administration, Intravenous; Adult; Asian People; Double-Blind Method; Female; Ferric Compounds; Humans; Iron; Male; Maltose; Middle Aged; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Trace Elements; Treatment Outcome | 2016 |
Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disaccharides; Drug Hypersensitivity; Female; Ferric Compounds; Humans; Hypophosphatemia; Infusions, Intravenous; Male; Maltose; Middle Aged; Prevalence; Retrospective Studies; Young Adult | 2017 |
Distinct in vitro Complement Activation by Various Intravenous Iron Preparations.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Complement Activation; Complement C1q; Complement C3d; Complement Membrane Attack Complex; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Humans; In Vitro Techniques; Iron Compounds; Iron-Dextran Complex; Kidney Failure, Chronic; Maltose; Mannose-Binding Lectin; Properdin; Renal Dialysis | 2017 |
Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.
Topics: Administration, Intravenous; Adult; Aged; Anemia, Iron-Deficiency; Biomarkers; Disaccharides; Female; Ferric Compounds; Fibroblast Growth Factor-23; Humans; Hypophosphatemia; Male; Maltose; Middle Aged; Phosphates; Prevalence; Retrospective Studies; Risk | 2016 |
Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study).
Topics: Adult; Aged; Anemia; Erythrocyte Transfusion; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; France; Glucaric Acid; Hematologic Neoplasms; Hemoglobins; Humans; Male; Maltose; Middle Aged; Neoplasms; Retrospective Studies | 2017 |
Definition of functional iron deficiency and intravenous iron supplementation.
Topics: Anemia; Anemia, Iron-Deficiency; Dietary Supplements; Ferric Compounds; Humans; Iron; Maltose; Prospective Studies | 2016 |
A fast-track anaemia clinic in the Emergency Department: cost-analysis of intravenous iron administration for treating iron-deficiency anaemia.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Costs and Cost Analysis; Emergency Service, Hospital; Female; Ferric Compounds; Humans; Iron; Male; Maltose; Middle Aged | 2017 |
Safety and efficacy of ferric carboxymaltose in children and adolescents with iron deficiency anemia.
Topics: Adolescent; Anemia, Iron-Deficiency; Child; Ferric Compounds; Humans; Iron; Maltose | 2017 |
Early Postdischarge STOP-HF-Clinic Reduces 30-day Readmissions in Old and Frail Patients With Heart Failure.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Cardiotonic Agents; Diuretics; Erythrocyte Transfusion; Female; Ferric Compounds; Frail Elderly; Furosemide; Heart Failure; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Patient Discharge; Patient Readmission; Prospective Studies; Referral and Consultation; Secondary Prevention | 2017 |
Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation.
Topics: Adult; Aged; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypophosphatemia; Kidney Transplantation; Male; Maltose; Phosphates; Postoperative Complications | 2017 |
Blood and Bone Loser.
Topics: Administration, Intravenous; Anti-Inflammatory Agents; Biopsy; Crohn Disease; Digestive System Surgical Procedures; Drug Therapy, Combination; Femoral Neck Fractures; Ferric Compounds; Gastrointestinal Agents; Hematinics; Humans; Hypophosphatemia; Hypophosphatemia, Familial; Magnetic Resonance Imaging; Male; Maltose; Middle Aged; Osteomalacia; Postoperative Hemorrhage | 2017 |
Patient Blood Management in Major Orthopedic Surgery: Less Erythropoietin and More Iron?
Topics: Aged; Aged, 80 and over; Anemia; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biomarkers; Blood Loss, Surgical; Blood Transfusion; Drug Administration Schedule; Drug Compounding; Erythropoietin; Female; Ferric Compounds; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Maltose; Middle Aged; Program Evaluation; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2017 |
[Iron deficiency : a new target in treating chronic heart failure ?]
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Chronic Disease; Ferric Compounds; Heart Failure; Hospitalization; Humans; Iron Deficiencies; Maltose; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic | 2016 |
Iron substitution in the treatment of chronic heart failure.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Chronic Disease; Comorbidity; Ferric Compounds; Heart Failure; Hospitalization; Humans; Iron Deficiencies; Maltose; Prognosis; Randomized Controlled Trials as Topic | 2017 |
Sustainability of Endovenous Iron Deficiency Anaemia Treatment: Hospital-Based Health Technology Assessment in IBD Patients.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Ferric Compounds; Hemoglobins; Hospitals; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Iron; Italy; Maltose; Technology Assessment, Biomedical; Treatment Outcome | 2017 |
Therapy experiences and preferences among patients with anemia: Results of a cross-sectional survey among Italian patients with inflammatory bowel disease.
Topics: Absenteeism; Administration, Intravenous; Administration, Oral; Adult; Anemia; Caregivers; Cost of Illness; Cross-Sectional Studies; Employment; Female; Ferric Compounds; Health Care Surveys; Hemoglobins; Humans; Inflammatory Bowel Diseases; Iron; Male; Maltose; Middle Aged; Patient Preference; Severity of Illness Index | 2017 |
Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre.
Topics: Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Female; Ferric Compounds; Hematinics; Humans; Infant; Infusions, Intravenous; Male; Maltose; Retrospective Studies; Tertiary Care Centers; Treatment Outcome; United Kingdom | 2017 |
Influence of combined iron supplementation and simulated hypoxia on the haematological module of the athlete biological passport.
Topics: Adult; Altitude; Athletes; Biomarkers; Dietary Supplements; Doping in Sports; Erythropoiesis; Female; Ferric Compounds; Hemoglobins; Humans; Hypoxia; Iron; Male; Maltose; Reticulocytes; Substance Abuse Detection; Young Adult | 2018 |
Diagnosis and treatment of iron-deficiency anaemia in pregnancy and postpartum.
Topics: Administration, Intravenous; Administration, Oral; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Humans; Iron; Maltose; Postpartum Period; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Severity of Illness Index; Treatment Outcome | 2017 |
Ferric Carboxymaltose to Treat Isovolemic Anemia.
Topics: Anemia; Anemia, Iron-Deficiency; Ferric Compounds; Humans; Maltose | 2017 |
Ferric Carboxymaltose to Treat Isovolemic Anemia-Reply.
Topics: Anemia; Anemia, Iron-Deficiency; Ferric Compounds; Humans; Maltose | 2017 |
"Pumping Iron" to Improve Exercise Performance in Heart Failure: New Data and New Guidelines.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Heart Failure; Humans; Iron; Maltose | 2017 |
Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia.
Topics: Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Maltose; Nepal; Pregnancy; Pregnancy Complications, Hematologic; Prospective Studies; Socioeconomic Factors; Young Adult | 2017 |
Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.
Topics: Anemia, Iron-Deficiency; Budgets; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Inflammatory Bowel Diseases; Infusions, Intravenous; Iron-Dextran Complex; Maltose; Retrospective Studies; United Kingdom | 2017 |
Intravenous ferric carboxymaltose for heart failure with iron deficiency.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Heart Failure; Humans; Iron; Maltose | 2018 |
Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound.
Topics: Administration, Intravenous; Animals; Blood Pressure; Cardiovascular System; Ferric Compounds; Kidney; Liver; Maltose; Rats; Rats, Sprague-Dawley | 2017 |
Safety and efficacy of parenteral iron in children with inflammatory bowel disease.
Topics: Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Female; Ferric Compounds; Ferric Oxide, Saccharated; Hemoglobins; Humans; Infusions, Intravenous; Male; Maltose; Retrospective Studies; Transferrin | 2018 |
Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Crohn Disease; Diagnosis, Differential; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypophosphatemia; Male; Maltose; Middle Aged; Osteomalacia; Phosphates; Treatment Outcome | 2018 |
Increased Plasmodium chabaudi malaria mortality in mice with nutritional iron deficiency can be reduced by short-term adjunctive iron supplementation.
Topics: Animals; Dietary Supplements; Ferric Compounds; Fibroblast Growth Factor-23; Iron Deficiencies; Malaria; Male; Malnutrition; Maltose; Mice; Plasmodium chabaudi; Specific Pathogen-Free Organisms | 2018 |
Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Asian People; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Ferric Compounds; Hematopoiesis; Humans; Infusions, Intravenous; Iron; Male; Maltose; Middle Aged; Reticulocyte Count; Safety; Young Adult | 2018 |
Bioequivalence decision for nanoparticular iron complex drugs for parenteral administration based on their disposition.
Topics: Amylopectin; Animals; Embryo, Nonmammalian; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Iron-Dextran Complex; Kidney; Liver; Maltose; Models, Animal; Myocardium; Nanoparticles; Therapeutic Equivalency; Turkey | 2018 |
Inflammatory bowel disease and anemia: intravenous iron treatment.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Exanthema; Female; Ferric Compounds; Ferritins; Finland; Humans; Inflammatory Bowel Diseases; Iron; Linear Models; Male; Maltose; Middle Aged; Nausea; Receptors, Transferrin; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Retrospective cohort study comparing the adverse reactions and efficacy of intravenous iron polymaltose with ferric carboxymaltose for iron deficiency anemia.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Australia; Cohort Studies; Female; Ferric Compounds; Humans; Maltose; Middle Aged; Pregnancy; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
Topics: Administration, Intravenous; Aged; Anemia, Iron-Deficiency; Drug Costs; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Inpatients; Length of Stay; Male; Maltose; Middle Aged; Retrospective Studies | 2018 |
Intravenous Iron Does Not Augment the Hemoglobin Mass Response to Simulated Hypoxia.
Topics: Adaptation, Physiological; Administration, Intravenous; Administration, Oral; Adult; Altitude; Dietary Supplements; Erythropoietin; Female; Ferric Compounds; Ferrous Compounds; Hemoglobins; Humans; Hypoxia; Male; Maltose; Physical Conditioning, Human; Physical Endurance; Young Adult | 2018 |
Postoperative Intravenous Ferric Carboxymaltose Reduces Transfusion Amounts after Orthopedic Hip Surgery.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Female; Ferric Compounds; Hemoglobins; Hip Joint; Humans; Length of Stay; Male; Maltose; Middle Aged; Postoperative Care; Postoperative Complications; Propensity Score; Retrospective Studies; Young Adult | 2018 |
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Infant, Newborn; Infusions, Intravenous; Iron Deficiencies; Maltose; Pregnancy; Pregnancy Complications, Hematologic; Pregnant Women; Prenatal Care; Prospective Studies; Treatment Outcome | 2018 |
Impact of ferric carboxymaltose on the evolution of hemoglobin and ECOG performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Blood Transfusion; Female; Ferric Compounds; Ferritins; Follow-Up Studies; Health Status Indicators; Hemoglobins; Humans; Male; Maltose; Middle Aged; Neoplasms; Quality of Life; Retrospective Studies; Young Adult | 2018 |
Use of intravenous iron in cyanotic patients with congenital heart disease and/or pulmonary hypertension.
Topics: Administration, Intravenous; Adult; Aged; Drug Monitoring; Erythropoiesis; Female; Ferric Compounds; Heart Defects, Congenital; Hematinics; Hematologic Tests; Humans; Hypertension, Pulmonary; Iron; Iron Deficiencies; Male; Maltose; Middle Aged; Polycythemia; Retrospective Studies; Treatment Outcome; United Kingdom | 2018 |
Budget Impact Analysis of Oral Fisiogen Ferro Forte
Topics: Administration, Intravenous; Administration, Oral; Adult; Anemia, Iron-Deficiency; Budgets; Cost Savings; Ferric Compounds; Health Care Costs; Hospitalization; Humans; Iron; Kidney Transplantation; Maltose; Models, Economic; Peritoneal Dialysis; Renal Insufficiency, Chronic; Spain | 2018 |
Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Colitis, Ulcerative; Crohn Disease; Female; Ferric Compounds; Ferritins; Hemoglobins; Humans; Male; Maltose; Middle Aged; Prospective Studies; Quality of Life; Severity of Illness Index; Transferrin; Young Adult | 2018 |
A comment on the comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Ferrosoferric Oxide; Humans; Maltose | 2018 |
A response by Strauss et al. to "a comment on the comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia".
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Ferrosoferric Oxide; Humans; Maltose | 2018 |
Iron supplementation in a case of severe iron deficiency anaemia.
Topics: Administration, Intravenous; Aged; Anemia, Iron-Deficiency; Ferric Compounds; Hemoglobins; Humans; Iron; Male; Maltose | 2018 |
Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women.
Topics: Administration, Intravenous; Administration, Oral; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferrous Compounds; Hemoglobins; Humans; Maltose; Pregnancy; Pregnancy Complications, Hematologic; Republic of Korea; Young Adult | 2018 |
Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients.
Topics: Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Drug Substitution; Female; Ferric Compounds; Ferric Oxide, Saccharated; Hematinics; Humans; Iron; Longitudinal Studies; Male; Maltose; Middle Aged; Netherlands; Renal Dialysis; Retrospective Studies | 2018 |
Clinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleeding.
Topics: Aged; Aged, 80 and over; Anemia; Biomarkers; Blood Transfusion; Erythropoiesis; Female; Ferric Compounds; Gastrointestinal Hemorrhage; Hematinics; Hemoglobins; Humans; Infusions, Intravenous; Length of Stay; Male; Maltose; Middle Aged; Patient Admission; Retrospective Studies; Spain; Time Factors; Treatment Outcome | 2019 |
Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.
Topics: Anemia, Iron-Deficiency; Female; Ferric Compounds; Hemoglobins; Humans; Iron; Maltose; Pregnancy | 2018 |
Skeletal Muscle Abnormalities and Iron Deficiency in Chronic Heart Failure
Topics: Acidosis; Administration, Intravenous; Adult; Aged; Biomarkers; Case-Control Studies; Energy Metabolism; Exercise Test; Female; Ferric Compounds; Heart Failure; Humans; Iron; Iron Deficiencies; Isometric Contraction; Leg; Magnetic Resonance Spectroscopy; Male; Maltose; Middle Aged; Muscle, Skeletal; Phosphorus Isotopes; Predictive Value of Tests; Time Factors; Treatment Outcome | 2018 |
Response to letter to the Editor: Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Maltose; Pregnancy | 2018 |
Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
Topics: Adult; Aged; Anemia, Iron-Deficiency; Comorbidity; Disaccharides; Drug Hypersensitivity; Female; Ferric Compounds; Hematinics; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Netherlands; Prospective Studies; Risk Factors | 2019 |
An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Denmark; Disaccharides; Female; Ferric Compounds; Hemoglobins; Humans; Inflammatory Bowel Diseases; Maltose; Middle Aged; Retrospective Studies | 2018 |
Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries.
Topics: Aged; Anemia, Iron-Deficiency; Clinical Trials, Phase III as Topic; Cost Savings; Cost-Benefit Analysis; Drug Costs; Female; Ferric Compounds; Guideline Adherence; Heart Failure; Hematinics; Humans; Male; Maltose; Models, Economic; Practice Guidelines as Topic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Registries; Scandinavian and Nordic Countries; Time Factors; Treatment Outcome | 2018 |
Cytarabine and Ferric Carboxymaltose (Fe+3) Increase Oxidative Damage and Alter Serotonergic Metabolism in Brain.
Topics: Animals; Brain; Cytarabine; Dopamine; Ferric Compounds; Hydrogen Peroxide; Lipid Peroxidation; Maltose; Oxidation-Reduction; Oxidative Stress; Rats, Wistar; Serotonin | 2019 |
Effectiveness of outpatient treatment with intravenous iron in selected primary Care patients.
Topics: Administration, Intravenous; Adult; Aged, 80 and over; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Hematinics; Humans; Male; Maltose; Middle Aged | 2020 |
Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017.
Topics: Databases, Factual; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Europe; Ferric Compounds; Humans; Isomaltose; Maltose; Pharmacovigilance; Retrospective Studies; Severity of Illness Index | 2019 |
Iron-deficiency anemia reduces cardiac contraction by downregulating RyR2 channels and suppressing SERCA pump activity.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Animals; Calcium; Calcium-Binding Proteins; Cells, Cultured; Disease Models, Animal; Down-Regulation; Ferric Compounds; Heart Failure; Humans; Iron; Magnetic Resonance Imaging; Male; Maltose; Mice; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Primary Cell Culture; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Stroke Volume | 2019 |
[Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Cohort Studies; Female; Ferric Compounds; Follow-Up Studies; Hematinics; Hospitals, General; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Renal Insufficiency, Chronic | 2019 |
Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
Topics: Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Drug Monitoring; Female; Ferric Compounds; Ferritins; Hematinics; Humans; Infusions, Intravenous; Iron; Male; Maltose; Middle Aged; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Transferrin | 2019 |
Authors' reply to Schaffalitzky de Muckadell and colleague's Comment on "Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilan
Topics: Europe; Ferric Compounds; Iron; Maltose | 2019 |
Comment on 'Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ Between 2014 and 2017'.
Topics: Europe; Ferric Compounds; Iron; Maltose | 2019 |
Extravasation and pigmentation post iron infusion.
Topics: Anemia, Iron-Deficiency; Extravasation of Diagnostic and Therapeutic Materials; Female; Ferric Compounds; Humans; Infusions, Intravenous; Maltose; Middle Aged; Pigmentation Disorders | 2019 |
Circumferential Ulcerations in the Ascending Colon.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colon; Colonic Diseases; Colonoscopy; Diclofenac; Female; Ferric Compounds; Humans; Intestinal Mucosa; Maltose; Proton Pump Inhibitors; Tomography, X-Ray Computed; Treatment Outcome; Ulcer | 2019 |
Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.
Topics: Administration, Intravenous; Aged; Chronic Disease; Cost Savings; Ferric Compounds; France; Heart Failure; Humans; Iron Deficiencies; Iron Metabolism Disorders; Maltose; Models, Economic | 2019 |
Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Topics: Anemia, Iron-Deficiency; Cost-Benefit Analysis; Denmark; Disaccharides; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Maltose | 2019 |
Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Topics: Anemia, Iron-Deficiency; Cost-Benefit Analysis; Denmark; Disaccharides; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Maltose | 2019 |
Intravenous Iron Use in the Care of Patients with Kidney Disease.
Topics: Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferric Oxide, Saccharated; Hematinics; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Renal Insufficiency, Chronic | 2019 |
Skin staining following intravenous iron infusion.
Topics: Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Infusions, Intravenous; Maltose; Pregnancy; Pregnancy Trimester, First; Skin Pigmentation | 2019 |
Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Disaccharides; Female; Ferric Compounds; Humans; Hypophosphatemia; Incidence; Inflammatory Bowel Diseases; Male; Maltose; Middle Aged; Norway; Prospective Studies; Quality of Life; Risk Factors | 2019 |
Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia.
Topics: Disaccharides; Ferric Compounds; Humans; Hypophosphatemia; Incidence; Inflammatory Bowel Diseases; Iron; Maltose | 2019 |
Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia. Authors' reply.
Topics: Disaccharides; Ferric Compounds; Humans; Hypophosphatemia; Incidence; Inflammatory Bowel Diseases; Iron; Maltose | 2019 |
Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Budgets; Chronic Disease; Cost-Benefit Analysis; Ferric Compounds; Heart Failure; Humans; Italy; Maltose; Markov Chains; Models, Econometric | 2019 |
Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
Topics: Administration, Oral; Animals; beta-Globins; beta-Thalassemia; Cation Transport Proteins; Cell Line; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Erythropoiesis; Female; Ferric Compounds; Hepcidins; Humans; Iron; Madin Darby Canine Kidney Cells; Male; Maltose; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Proteolysis; Rats, Sprague-Dawley; Ubiquitination | 2019 |
Treatment with ferric carboxymaltose in stable patients with severe iron deficiency anemia in the emergency department.
Topics: Adolescent; Adult; Anemia, Iron-Deficiency; Emergency Service, Hospital; Female; Ferric Compounds; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Retrospective Studies | 2020 |
Letter to the Editor.
Topics: Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Ferric Compounds; Humans; Male; Maltose | 2019 |
Ferric Carboxymaltose in the treatment of chemotherapy-induced anaemia: an effective, safe and cost- sparing alternative to blood transfusion.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Female; Ferric Compounds; Humans; Male; Maltose; Middle Aged; Neoplasms; Quality of Life; Retrospective Studies; Treatment Outcome | 2019 |
Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia.
Topics: Adult; Anemia, Iron-Deficiency; Antibodies, Monoclonal, Humanized; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypophosphatemia; Male; Maltose; Osteomalacia; Treatment Outcome | 2020 |
Hypophosphatemia in children treated with ferric carboxymaltose.
Topics: Anemia, Iron-Deficiency; Child; Ferric Compounds; Humans; Hypophosphatemia; Maltose | 2020 |
Sparing unnecessary transfusions through patient blood management: time for application also in internal and emergency medicine.
Topics: Anemia, Iron-Deficiency; Blood Transfusion; Emergency Medicine; Emergency Service, Hospital; Ferric Compounds; Humans; Maltose | 2020 |
Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland.
Topics: Administration, Intravenous; Ambulatory Care Facilities; Anemia, Iron-Deficiency; Costs and Cost Analysis; Disaccharides; Ferric Compounds; Health Resources; Humans; Ireland; Maltose; Models, Economic; Preoperative Care | 2020 |
Effect of intravenous iron replacement therapy on exercise capacity in iron deficient anemic patients after cardiac surgery.
Topics: Aged; Anemia, Iron-Deficiency; Cardiac Surgical Procedures; Exercise Tolerance; Female; Ferric Compounds; Hematinics; Humans; Infusions, Intravenous; Male; Maltose; Middle Aged; Retrospective Studies; Treatment Outcome | 2020 |
Intravenous ferric carboxymaltose for iron deficiency anemia in dialysis patients: Effect of a new protocol adopted for a hemodialysis limited assistance center.
Topics: Administration, Intravenous; Ambulatory Care Facilities; Anemia, Iron-Deficiency; Clinical Protocols; Costs and Cost Analysis; Erythropoietin; Female; Ferric Compounds; Ferritins; Hematinics; Humans; Iron; Italy; Male; Maltose; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2020 |
Preventing skin staining: an effective iron infusion protocol.
Topics: Clinical Protocols; Coloring Agents; Extravasation of Diagnostic and Therapeutic Materials; Female; Ferric Compounds; Health Personnel; Humans; Infusions, Intravenous; Maltose; Patient Education as Topic; Pregnancy; Quality Improvement; Skin | 2020 |
Desensitization in Iron Product Allergy.
Topics: Adult; Anemia, Iron-Deficiency; Chlorpheniramine; Dexamethasone; Female; Ferric Compounds; Hematinics; Humans; Hypersensitivity; Iron; Maltose; Middle Aged; Skin Tests | 2020 |
Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage.
Topics: Biomarkers; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Heart Failure; Humans; Hypophosphatemia; Injections, Intravenous; Maltose; Stroke Volume | 2020 |
High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study.
Topics: Adult; Aged; Anemia, Iron-Deficiency; Bariatric Surgery; Female; Ferric Compounds; Fibroblast Growth Factor-23; Humans; Hypophosphatemia; Maltose; Middle Aged; Obesity, Morbid; Prospective Studies; Young Adult | 2020 |
Acute generalized exanthematous pustulosis induced by iron carboxymaltose infusion: A case report.
Topics: Acute Generalized Exanthematous Pustulosis; Ferric Compounds; Humans; Maltose | 2020 |
Successful Treatment of Iatrogenic Cutaneous Siderosis with Pigment Lasers: A Retrospective Study in 15 Consecutive Patients.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Extravasation of Diagnostic and Therapeutic Materials; Female; Ferric Compounds; Hematinics; Humans; Iatrogenic Disease; Lasers, Solid-State; Low-Level Light Therapy; Maltose; Middle Aged; Retrospective Studies; Siderosis; Skin Diseases; Treatment Outcome; Young Adult | 2020 |
Case report: A rare cause of severe hypophosphatemia.
Topics: Administration, Oral; Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Hypophosphatemia; Infusions, Intravenous; Maltose; Middle Aged; Phosphates; Severity of Illness Index; Vitamin D Deficiency | 2020 |
Preoperative Intravenous Iron and Erythropoietin to Treat Severe Anemia in Patient With Stage 4 Kidney Disease Before Oncologic Surgery: A Case Report.
Topics: Administration, Intravenous; Anemia; Endometrial Neoplasms; Erythropoietin; Female; Ferric Compounds; Hemoglobins; Humans; Hysterectomy; Infusions, Intravenous; Iron; Kidney Diseases; Maltose; Middle Aged; Preoperative Care; Severity of Illness Index; Trace Elements; Treatment Outcome | 2020 |
Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Colitis, Ulcerative; Crohn Disease; Female; Ferric Compounds; Humans; Hypophosphatemia; Incidence; Male; Maltose; Middle Aged; Nutritional Status; Phosphates; Prospective Studies; Risk Factors; Treatment Outcome; Vitamin D; Young Adult | 2020 |
Iron deficiency and safety of ferric carboxymaltose in patients with acute heart failure. AHF-ID study.
Topics: Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Heart Failure; Humans; Male; Maltose; Middle Aged; Prospective Studies; Treatment Outcome | 2020 |
Efficacy and safety of high-dose intravenous iron as the first-choice therapy in outpatients with severe iron deficiency anemia.
Topics: Administration, Intravenous; Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Hemoglobins; Humans; Iron; Male; Maltose; Middle Aged; Outpatients; Retrospective Studies; Severity of Illness Index | 2020 |
Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: Benefits and risks in a cohort of 144 children and adolescents.
Topics: Administration, Intravenous; Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Female; Ferric Compounds; Follow-Up Studies; Humans; Infant; Iron Metabolism Disorders; Male; Maltose; Prognosis; Retrospective Studies | 2020 |
Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.
Topics: Anemia, Iron-Deficiency; Female; Ferric Compounds; Fibroblast Growth Factor-23; Humans; Maltose; Minerals | 2020 |
Fatal anaphylactic reaction due to ferric carboxymaltose: A case report.
Topics: Aged; Anaphylaxis; Anemia, Iron-Deficiency; Fatal Outcome; Ferric Compounds; Humans; Male; Maltose | 2020 |
The Impact of the Ferric Carboxymaltose on Hemoglobin and Ferritin Levels.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Ferritins; Hemoglobins; Humans; Maltose | 2020 |
Ferric carboxymaltose (Ferinject®) associated hypophosphataemia: case report illustrating the need for increased awareness to minimise incidence and risk.
Topics: Ferric Compounds; Humans; Hypophosphatemia; Incidence; Maltose | 2020 |
Comparison between oral ferrous sulfate and intravenous ferric carboxymaltose in children with restless sleep disorder.
Topics: Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Ferric Compounds; Ferrous Compounds; Humans; Maltose; Pilot Projects; Retrospective Studies; Sleep Wake Disorders | 2021 |
Ferric carboxymaltose for sub-acute and chronic iron deficiency anemia in inherited platelet function defects.
Topics: Administration, Intravenous; Adult; Aged; Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Maltose; Thrombasthenia | 2021 |
Patient characteristics predicting responses to intravenous ferric carboxymaltose treatment of restless legs syndrome.
Topics: Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Maltose; Restless Legs Syndrome; Retrospective Studies; Treatment Outcome | 2020 |
Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
Topics: Administration, Oral; Anemia, Iron-Deficiency; Cost Savings; Cost-Benefit Analysis; Decision Support Systems, Clinical; Drug Prescriptions; Ferric Compounds; Ferric Oxide, Saccharated; France; Health Plan Implementation; Hematinics; Hospital Costs; Hospitalization; Humans; Infusions, Intravenous; Interrupted Time Series Analysis; Iron; Maltose; Pharmacy Service, Hospital; Program Evaluation; Treatment Outcome | 2021 |
Comment on: Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: Benefits and risks in a cohort of 144 children and adolescents.
Topics: Administration, Intravenous; Adolescent; Anemia; Anemia, Iron-Deficiency; Child; Ferric Compounds; Humans; Iron; Maltose; Risk Assessment | 2021 |
Comparison of the maternal and neonatal outcomes of pregnant women whose anemia was not corrected before delivery and pregnant women who were treated with intravenous iron in the third trimester.
Topics: Adult; Anemia; Case-Control Studies; Cesarean Section; Female; Ferric Compounds; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Small for Gestational Age; Injections, Intravenous; Iron; Maltose; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pregnancy Trimester, Third; Pregnant Women; Retrospective Studies; Turkey | 2021 |
Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.
Topics: Adult; Aged; Creatinine; Female; Ferric Compounds; Heart Failure; Humans; Hypophosphatemia; Infusions, Intravenous; Iron Deficiencies; Male; Maltose; Middle Aged; Phosphates; Retrospective Studies; Stroke Volume; Time Factors | 2021 |
Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Heart Failure; Humans; Iron; Maltose; Prospective Studies; Quality of Life; Spain; Stroke Volume; Ventricular Function, Left | 2020 |
"Camel humps"-shaped red blood cell histogram in a woman with extreme anemia treated with intravenous iron.
Topics: Aged; Anemia; Erythrocyte Volume; Erythrocytes, Abnormal; Female; Ferric Compounds; Gastrointestinal Hemorrhage; Hemoglobins; Hemorrhoids; Humans; Infusions, Intravenous; Leucovorin; Maltose; Rectum; Reticulocyte Count; Vitamin B 12 | 2021 |
Ferric Carboxymaltose Across All Ages in Paediatric Gastroenterology Shows Efficacy Without Increased Safety Concerns.
Topics: Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Ferric Compounds; Gastroenterology; Humans; Infusions, Intravenous; Male; Maltose; Retrospective Studies | 2021 |
An Optimized Process for the Preparation of Aqueous Ferric Carboxymaltose: Synthesis and Structural Characterization.
Topics: Ferric Compounds; Iron; Maltose; Water; X-Ray Diffraction | 2021 |
Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
Topics: Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Ferric Oxide, Saccharated; Humans; Iron Deficiencies; Maltose | 2022 |
Heart failure or heart success?
Topics: Cardiovascular Agents; Evidence-Based Medicine; Ferric Compounds; Glycosides; Heart Failure, Systolic; Hospitalization; Humans; Maltose; Randomized Controlled Trials as Topic; Recovery of Function; Research Design; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Urea; Ventricular Function, Left | 2021 |
Iron heart.
Topics: Anemia, Iron-Deficiency; Double-Blind Method; Ferric Compounds; Heart Failure; Humans; Iron; Maltose; Patient Discharge | 2021 |
Refractory hypophosphatemia following ferric carboxymaltose administration.
Topics: Administration, Intravenous; Adult; Colitis, Ulcerative; Female; Ferric Compounds; Humans; Hypophosphatemia; Maltose; Phosphates | 2021 |
Preoperative Intravenous Iron in Anemic Patients Undergoing Major Abdominal Surgery May Not PREVENTT Blood Transfusions But Still Contribute to the Objectives of Patient Blood Management.
Topics: Abdomen; Administration, Intravenous; Anemia; Biomarkers; Blood Loss, Surgical; Blood Transfusion; Drug Administration Schedule; Ferric Compounds; Hematinics; Hemoglobins; Humans; Maltose; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2021 |
Phosphorus levels in children treated with intravenous ferric carboxymaltose.
Topics: Adolescent; Age Factors; Anemia, Iron-Deficiency; Child; Child, Preschool; Female; Ferric Compounds; Humans; Hypophosphatemia; Infant; Infusions, Intravenous; Male; Maltose; Phosphorus; Retrospective Studies; Young Adult | 2021 |
Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
Topics: Administration, Intravenous; Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Female; Ferric Compounds; Ferritins; Hemoglobins; Humans; Hypophosphatemia; Inflammatory Bowel Diseases; Iron; Male; Maltose; Phosphates; Prevalence; Risk Factors; Severity of Illness Index; Treatment Outcome | 2021 |
Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis.
Topics: Aged; Anemia; Costs and Cost Analysis; Darbepoetin alfa; Ferric Compounds; Ferrous Compounds; Hematologic Tests; Hemoglobins; Humans; Iron; Maltose; Renal Insufficiency, Chronic; Retrospective Studies; Time Factors; Treatment Outcome | 2021 |
In acute HF and iron deficiency, IV ferric carboxymaltose reduced HF hospitalizations, but not CV death, at 1 y.
Topics: Anemia, Iron-Deficiency; Double-Blind Method; Ferric Compounds; Heart Failure; Hospitalization; Humans; Maltose; Patient Discharge | 2021 |
Attitude changes in prescribing intravenous iron supplementation in different settings at a hospital consortium in Italy.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Costs and Cost Analysis; Drug Prescriptions; Female; Ferric Compounds; Ferrous Compounds; Humans; Male; Maltose | 2021 |
Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design.
Topics: Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Heart Failure; Humans; Male; Maltose; Middle Aged; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left | 2021 |
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
Topics: Cost-Benefit Analysis; Ferric Compounds; Heart Failure; Humans; Iron Deficiencies; Maltose; Quality of Life; Stroke Volume; Ventricular Function, Left | 2021 |
Intravenous iron is non-inferior to oral iron regarding cell growth and iron metabolism in colorectal cancer associated with iron-deficiency anaemia.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Cell Proliferation; Colorectal Neoplasms; Female; Ferric Compounds; Ferrous Compounds; Humans; Iron; Male; Maltose; Middle Aged | 2021 |
Intravenous ferric carboxymaltose does not provide benefits in reperfused acute myocardial infarction in the rat with normal iron status.
Topics: Administration, Intravenous; Animals; Arrhythmias, Cardiac; Echocardiography; Ferric Compounds; Hemodynamics; Hypertrophy, Left Ventricular; Iron; Male; Maltose; Mitochondria, Heart; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Oxidative Stress; Rats; Rats, Wistar; Ventricular Remodeling | 2021 |
Hypophosphataemia Following Ferric Carboxymaltose Infusion.
Topics: Ferric Compounds; Humans; Hypophosphatemia; Maltose | 2021 |
Clinical effects and safety of ferric carboxymaltose in pregnancy: An Indian real-life experience.
Topics: Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Infant, Newborn; Maltose; Pregnancy; Retrospective Studies; Treatment Outcome | 2021 |
Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
Topics: Administration, Intravenous; Adult; Aged; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Female; Ferric Compounds; Ferric Oxide, Saccharated; Health Expenditures; Humans; Male; Maltose; Middle Aged; Treatment Outcome; Young Adult | 2021 |
A budget impact analysis of iron polymaltose and ferric carboxymaltose infusions.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Humans; Infusions, Intravenous; Maltose | 2022 |
Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study.
Topics: Adult; Aged; Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Iron Deficiencies; Male; Maltose; Middle Aged; Pulmonary Arterial Hypertension; Retrospective Studies | 2021 |
Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder.
Topics: Child; Ferric Compounds; Humans; Maltose; Nocturnal Myoclonus Syndrome; Restless Legs Syndrome; Retrospective Studies; Treatment Outcome | 2021 |
In patients with acute HF and iron deficiency, IV ferric carboxymaltose improved quality of life at 4 to 24 wk.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Heart Failure; Humans; Maltose; Quality of Life | 2021 |
Letter to "Clinical effects and safety of ferric carboxymaltose in pregnancy: An Indian real-life experience".
Topics: Female; Ferric Compounds; Humans; Maltose; Pregnancy | 2022 |
Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
Topics: Alkaline Phosphatase; Anemia, Iron-Deficiency; Biomarkers; Calcium; Disaccharides; Familial Hypophosphatemic Rickets; Female; Ferric Compounds; Humans; Hypophosphatemia; Iron; Male; Maltose; Minerals; Osteomalacia; Parathyroid Hormone; Risk Factors | 2022 |
Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction.
Topics: Ferric Compounds; Heart Failure; Humans; Maltose; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2022 |
Effectiveness and safety of an on-demand ferric carboxymaltose infusion strategy in patients with inflammatory bowel disease: a real world experience.
Topics: Anemia, Iron-Deficiency; Chronic Disease; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Male; Maltose; Retrospective Studies; Treatment Outcome | 2022 |
Hypophosphatemic osteomalacia, a side effect of iron carboxymaltose administration.
Topics: Ferric Compounds; Humans; Hypophosphatemia; Iron; Maltose; Osteomalacia | 2022 |
Does Postoperative Intravenous Ferric Carboxymaltose Hasten the Recovery of Hemoglobin in Patients Post Total Knee Arthroplasty?
Topics: Anemia, Iron-Deficiency; Arthroplasty, Replacement, Knee; Ferric Compounds; Hemoglobins; Humans; Iron; Maltose; Retrospective Studies | 2022 |
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.
Topics: Ferric Compounds; Health Status; Heart Failure; Humans; Iron; Iron Deficiencies; Maltose; Quality of Life; Stroke Volume | 2022 |
Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Heart Failure; Humans; Iron; Iron Deficiencies; Maltose; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Walk Test | 2022 |
Analysis of transition from intravenous iron sucrose to ferric carboxymaltose infusions in pediatric patients with intestinal failure.
Topics: Anemia, Iron-Deficiency; Child; Ferric Compounds; Ferric Oxide, Saccharated; Humans; Infusions, Intravenous; Intestinal Failure; Iron; Maltose | 2022 |
Efficiency of intravenous iron carboxymaltose in patients with iron-deficiency anemia due to heavy menstrual bleeding: a single-center experience.
Topics: Anemia; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Hemoglobins; Humans; Iron; Maltose; Menorrhagia; Transferrins | 2022 |
Potential role of empagliflozin in myocardial iron repletion following ferric carboxymaltose for heart failure.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Heart Failure; Humans; Iron; Maltose | 2023 |
[A case of chronic enteropathy associated with SLCO2A1 gene diagnosed by capsule endoscopy and successfully treated by ferric carboxymaltose].
Topics: Anemia; Anemia, Iron-Deficiency; Capsule Endoscopy; Female; Ferric Compounds; Humans; Inflammatory Bowel Diseases; Iron; Maltose; Middle Aged; Organic Anion Transporters; Ulcer | 2022 |
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Heart Failure; Humans; Iron Deficiencies; Male; Maltose; Quality of Life | 2022 |
Effect of intravenous ferric carboxymaltose on exercise capacity and quality of life in patients with COPD : A pilot study.
Topics: Administration, Intravenous; Aged; Exercise Tolerance; Female; Ferric Compounds; Ferritins; Follow-Up Studies; Hemoglobins; Humans; Interrupted Time Series Analysis; Iron; Iron Deficiencies; Male; Maltose; Middle Aged; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quality of Life | 2023 |
High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.
Topics: Disaccharides; Ferric Compounds; Hormones; Humans; Hypophosphatemia; Iron; Maltose; Phosphates; Prospective Studies; Risk Assessment | 2022 |
A Novel Multicolor Flow Cytometry Scoring System for the Diagnosis and Prognostic Stratification of Myelodysplastic Syndromes.
Topics: Ferric Compounds; Flow Cytometry; Humans; Leukemia; Leukocyte Count; Maltose; Myelodysplastic Syndromes; Prognosis | 2022 |
Severe hypophosphatemia secondary to chronic treatment with endovenous ferric carboxymaltose.
Topics: Ferric Compounds; Humans; Hypophosphatemia; Maltose | 2022 |
The effect of immediate postoperative intravenous administration of ferric carboxymaltose after autologous free-flap breast reconstruction.
Topics: Administration, Intravenous; Breast Neoplasms; Female; Ferric Compounds; Humans; Maltose; Mammaplasty; Postoperative Complications; Retrospective Studies | 2022 |
Clinical, economical and safety impact of ferric carboxymaltose use in Patient Blood Management programme in Portuguese National Health Service hospitals.
Topics: Adult; Anemia; Anemia, Iron-Deficiency; Ferric Compounds; Hemoglobins; Hospitals; Humans; Iron; Maltose; Portugal; Retrospective Studies; State Medicine | 2022 |
Increases in Fibroblast Growth Factor 23 During Treatment With Ferric Carboxymaltose: Potential Adverse Effects on the Heart and Kidneys.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Fibroblast Growth Factor-23; Heart Failure; Humans; Kidney; Maltose | 2023 |
Hypersensitivity reactions associated with iron isomaltoside and ferric carboxymaltose.
Topics: Administration, Intravenous; Anemia, Iron-Deficiency; Disaccharides; Ferric Compounds; Humans; Maltose | 2023 |
Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation.
Topics: Anemia, Iron-Deficiency; Cost-Benefit Analysis; Ferric Compounds; Heart Failure; Hospitalization; Humans; Iron Deficiencies; Maltose; Patient Discharge; Quality of Life; Stroke Volume; Ventricular Function, Left | 2023 |
Ferric Carboxymaltose-mediated Methemoglobinemia.
Topics: Adult; Anemia, Iron-Deficiency; Female; Ferric Compounds; Humans; Maltose; Methemoglobin; Methemoglobinemia | 2024 |
Perioperative Tracking of Intravenous Iron in Patients Undergoing On-Pump Cardiac Surgery: A Prospective, Single-Center Pilot Trial.
Topics: Administration, Intravenous; Anemia; Cardiac Surgical Procedures; Female; Ferric Compounds; Humans; Iron; Male; Maltose; Pilot Projects; Prospective Studies | 2023 |
What is wrong in doing good?
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Humans; Hypophosphatemia; Iron; Maltose | 2023 |
Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
Topics: Ferric Compounds; Heart Failure; Humans; Iron Deficiencies; Maltose | 2023 |
Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
Topics: Ferric Compounds; Heart Failure; Humans; Iron Deficiencies; Maltose | 2023 |
Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
Topics: Ferric Compounds; Heart Failure; Humans; Iron Deficiencies; Maltose | 2023 |
Ferric Carboxymaltose in Heart Failure with Iron Deficiency. Reply.
Topics: Ferric Compounds; Heart Failure; Humans; Iron Deficiencies; Maltose | 2023 |